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1. Motivations and outline of the thesis 
 
Prion diseases are a group of invariably fatal disorders, for which there is no cure. Despite their rare 
incidence in humans, prion diseases have captured very large attention from the scientific 
community due to the unconventional mechanism by which they are transmitted.1 The central 
feature of prion diseases is the accumulation in the brain and some other tissues of the disease-
associated PrPSc, which is derived from the host-encoded cellular PrPC.1 The conversion from a 
normal form (PrPC) to an infectious isoform (scrapie, PrPSc) is triggered by the interaction between 
PrPC-PrPSc,2 as well as protein-protein interaction (PPI).3 
PrPC belongs to the class of amyloid-forming proteins, which are associated with a variety of 
conformational diseases. Indeed, prion diseases share many pathologic features with other 
neurodegenerative disorders. They are all characterized by the presence in the nervous system of 
abnormal protein accumulation. These abnormal proteins form aggregates of amyloid fibrils that 
continuously increase in size. This event changes the metabolic processes of neurons, ultimately 
leading to neurodegeneration. Conformational neurodegenerative disorders include Alzheimer’s 
disease (Aβ-amyloid neuritic plaques and neurofibrillary tangles), Parkinson’s disease (α-synuclein, 
Lewy bodies), Huntington’s disease (huntingtin protein aggregates) and Pick’s disease (Pick 
bodies).4-6 
As Prof. S. B. Prusiner recognizes already in his Nobel lecture in 1997, the ”Investigation of prion 
diseases suggest that new strategies for the prevention and treatment of these disorders may also 
find application in the more common degenerative disorders”.a Indeed, there is great interest in 
designing PrPSc blockers that may be also effective to prevent fibril formation in other 
neurodegenerative diseases.1 However, in spite of decades of attempts at developing effective anti-
prion drugs,7-10 no drug has been identified for prion treatment. Several are the challenges one has to 
face when developing such drugs.  
In this thesis, under the supervision of Prof. G. Legname, collaborator of Prof. S. B. Prusiner, Ib 
have focused on two of them. The first challenge concerns molecular docking approaches of ligands 
known already to bind PrPC. These studies are extremely difficult because of the lack of deep 
binding sites in PrPC. Molecular docking methodologies are well suited to predicted activity profiles 
and identifying binding poses.11 Unfortunately these approaches, whilst fast and useful for enzymes 
                                                      
a "The Nobel Prize in Physiology or Medicine 1997" http://nobelprize.org/nobel_prizes/medicine/laureates/1997/ 
b The research presented on this thesis was all performed as teamwork. 
 5 
and receptors, are likely to fail here because of the lack of a well-defined binding cavity: only 
shallow binding sites are present in the structure of PrPC (an issue addressed in Chapters 2 and 3). 
The second challenge (which constitutes the largest part of this thesis work) concerns the rational 
design of drug leads aimed at developing therapies for multifactorial diseases. Prion diseases, as 
other neurodegenerative diseases, are currently characterized as multifactorial disorders, where the 
pathogenic PrPC → PrPSc conversion is interrelated with multiple molecular mechanisms involving 
reactive oxygen species (ROS) production, an imbalance of brain metal homeostasis, and increased 
oxidation of lipids, proteins, and DNA (see Section 2.9).12 Therefore, the development of 
multifunctional antiprion compounds for prion diseases presents great challenges (this issue will be 
extensively addressed in Chapters 4-7) 
This thesis is organized as follows. 
Chapter 2 introduces prion diseases, PrPC and its role in the cell. This Chapter will also introduce 
therapeutic strategies for prion therapy. 
Chapters 3-4 present a novel computational protocol, called EMD (enhanced molecular docking) 
that combines standard docking methods with MD simulations and metadynamics based-free energy 
calculations in explicit solvent to address this issue.13,14 The EMD protocol provides a step forward 
towards the development of a tool able to identify small organic molecules that stabilize PrPC. I 
focused on 1 (2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-
acetamide, Figure 1A), which has been shown to bind by NMR to the structured part of the PrP, 
increasing its stability.15 The computational study enable to identify alternative binding poses that 
satisfy all of the contacts emerging from NMR, in contrast to a previous model. Most importantly, 
these results provided an estimation of the experimental free energy of binding that is in very good 
agreement with the experimental one. Prompted by the relevance of this issue, it has been tried to 
establish a computational protocol that attempts to include conformational selection16 and induced 
fit17 processes, which play an important role for 1 binding to PrPC, a protein lacking binding sites. 
Chapter 5 focuses on the rational design to discovering small organic molecules that attack prion 
diseases on multiple fronts. Prion diseases, like other neurodegenerative diseases, are currently 
characterized as multifactorial processes that operate simultaneously and synergistically in the cell 
environment finally leading to cell death.12 Indeed, the dominant drug discovery paradigm (one 
disease, one target, one molecule) ignores the polyetiological nature of many multifactorial diseases 
as well as prion diseases. Thus, this paradigm might be one possible factor behind the failure of 
many drugs to cure multifactorial diseases. In this respect, several lines of research have suggested 
that combination therapy (one disease, two or more targets, cocktail of drugs) or “multi-target-
directed ligand” (MTDL) strategy (one disease, two or more targets, one drug) that simultaneously 
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target more than one process might be a more effective therapeutic option.18 Section 5.2 
underscores advantages and disadvantages of the MTDL strategy.19	  To rational design MTDLs for 
prion diseases, I selected fragments with potential beneficial properties against PPI, unbalance of 
metal ions, and oxidative stress (OS). As PPI inhibitors, two hydrophobic heterocyclic motifs have 
been selected from literature. Quinoline and acridine are particularly frequent in compounds active 
against prion diseases.20 In particular, considering the key role of a planar hydrophobic structure in 
perturbing PPIs in all conformational diseases, it is conceivable that these hydrophobic motifs have 
the potential to disrupt PPIs also in prion diseases. The term “prion-recognition motif” (PRM ) will 
refer to a key fragment able to interact with prion proteins and to modulate PrPC misfolding (This 
aspect will be dealt in Section 5.5).  
The implication of OS in prion diseases suggested us the possibility to use antioxidant fragments to 
substitute and balance antioxidant deficiencies in the disease state. It has been argued that the 
presence of a PRM along with an antioxidant moiety might lead to discover more effective antiprion 
compounds. As a first effort to identify MTDLs with the simultaneous ability to prevent the 
conversion of PrPC to PrPSc form and to reduce oxidative stress, I present the rational design, 
synthesis and structure-activity relationship of two classes of antiprion compounds. In Chapter 6 
and 7, the structures of hit compounds representative the two classes are shown in Figure 1B (39 
and 64). Compounds 39 and 64 owing to the presence of an antioxidant fragment, the benzoquinone 
ring or the lipoyl group respectively, (highlighted in red in Figure 1B), and a PRM (highlighted in 
green), are studied as inhibitors of PrPSc formation and antioxidants in scrapie-infected mouse 
hypothalamus cells (ScGT1). Indeed, these compounds simultaneously modulate at least two of the 
multiple targets involved in prion pathology.21,22  
Chapter 8 discusses the rational design of an additional series of MTDLs potentially able to inhibit 
prion replication through multiple mechanisms.  
The conclusions are summarized in Chapter 9. 
The experimental section is discussed in Chapter 10. 
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Figure 1. A) Antiprion compound 1 acts on the conversion step by stabilizing the PrPC conformation and 
reducing the population of PrPSc. Illustration of the Gibbs free energy as a function of the conformational 
space to explain the inhibitory mechanism of 1. 1 stabilizes the PrPC conformation and reduces the population 
of PrPSc. The conformational space is multidimensional and only one arbitrary axis is shown here for the sake 
of clarity. B) Prion diseases pathogenesis involves a complex array of processes operating simultaneously and 
synergistically.12 These include: i) protein aggregation;2,24 ii) OS;25-27 iii) reduced levels of potent free-radical 
scavenger;28,29 iv) unbalance of metal ions;30,31 and v) brain inflammation.32 
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2. Introduction to Prion Diseases 
 
Prion diseases or transmissible spongiform encephalopathies (TSEs) are a group of neurological disorders, for 
which there is neither early diagnosis nor a cure.1,2 They include bovine spongiform encephalopathy (BSE) of 
cattle, scrapie of sheep, chronic wasting disease (CWD) of deer, moose and elk, Creutzfeldt-Jakob (CJD) and 
Gerstmann-Sträussler-Scheinker (GSS) diseases of humans.3 The human pathology has three distinct 
aetiologies: they might be autosomal dominantly inherited conditions; acquired from exposure to prions; or 
they might arise sporadically.4,5  
In the’90s, more than 280,000 cattle suffering from BSE (Figure 2)c provoked a worldwide food 
crisis with huge economic consequences for the European Union and other countries.6 	  
 
Figure 2. Incidence of BSE. Reported BSE cases in the United Kingdom (UK) and in countries and states 
excluding the UK. Non–United Kingdom BSE events include cases from countries of the European Union and 
outside the European Union (Canada, Israel, Liechtenstein, Japan, Switzerland, and the United States).  
 
                                                      
c http://www.oie.int/en/animal-health-in-the-world/bse-specific-data/number-of-reported-cases-worldwide-excluding-the-united-kingdom 
and http://www.oie.int/en/animal-health-in-the-world/bse-specific-data/number-of-cases-in-the-united-kingdom 
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In addition, transmission of BSE to humans is believed to have caused ≥ 200 cases of variant CJD 
(vCJD)d. In particular, vCJD has occurred in several areas of the world (see Figure 3). 
 
 
Figure 3. Geographic distribution of variant of Creutzfeldt-Jakob disease. vCJD occurs mainly in United 
Kingdom and France. The map was built from cases reported in the vCJD Web site.d Update to March 2011 
 
Prion diseases are characterized by widespread neurodegeneration; therefore, affected individuals or 
animals exhibit clinical symptoms of both cognitive and motor dysfunction. The typical 
microscopic features of prion diseases are vacuolation of the grey matter of the central nervous 
system (CNS), prominent neuronal loss, exuberant reactive astrogliosis and a variable degree of 
cerebral accumulation of PrPSc aggregates.1,2 
 
2.1. The prion-only hypothesis  
Despite their rare incidence, prion diseases have captured broad consideration from the scientific 
community due to the unorthodox mechanism by which prion diseases are transmitted. According 
to the “protein-only hypothesis”, in the CNS of the infected host, PrPC is converted into an 
abnormal insoluble amyloidogenic isoform, that is PrPSc or prion.2 The latter acts as a template for 
PrPC leading to nascent PrPSc molecules. The process of conversion is associated with 
                                                      
d http://www.cjd.ed.ac.uk/vcjdworld.htm 
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conformational changes of secondary structure from α-helices to β-sheets. The term “prion” (a 
small proteinaceous infectious particle that is resistant to inactivation by most procedures that 
modify nucleic acids) was proposed by Prof. S. B. Prusiner to distinguish the infectious pathogen 
that causes prion diseases from viruses and viroids.7 The infectious principle consists purely of 
protein and is capable of replicating and transmitting infections without the need for informational 
nucleic acids.7 Numerous experiments have provided evidence that PrPC is a key player in prion 
replication as well as in prion-induced neurodegeneration.8 PrPC expression is categorically required 
for neurodegeneration in host neurons, because the presence of PrPSc alone does not cause disease.9 
Indeed mice lacking the prion gene are resistant to the infection.10,11 
 
2.2. Structural chemistry of PrPC 
PrPC is a normal cell-surface glycoprotein linked to the plasma membrane by a 
glycosylphosphatidylinositol (GPI) membrane anchor. In humans, PrPC is a 253 amino acids (aa) 
protein (see Figure 4A), which has a molecular weight of 35-36 kDa. The preprotein PrPC is 
produced as a precursor protein containing two signals peptides. The 22 amino acids (signal 
peptide) at the N-terminus targets the protein to the endoplasmic reticulum, while the 23 amino acid 
sequence at the C-terminus is essential for the addition of the GPI moiety. Peptide 1–22 is cleaved 
as signal peptide during trafficking, and peptide 230–253 is replaced by the glycosyl-
phosphatidylinositol-anchor (see Figure 4A).7 Following the cleavage of the signal peptides, most 
of mammalian PrPC is exported to the cell surface as an N-glycosylated protein. 
As indicated in Figure 4B, PrPC containing an amino flexible, random coil sequence that spans 
approximately half of its amino-acid residues, and a carboxy C-terminal globular domain (GD) of 
about 100 aa, the major structural features of which are remarkably preserved among both 
mammalian and non-mammalian species. N-terminal PrPC contains two hexarepeats and five 
octarepeats. The octapeptide repeats can coordinate Cu2+ ions in cooperative fashion with high 
affinity, and display weaker binding properties towards other divalent cations, such as Zn2+, Fe2+, 
Mn2+ and Ni2+.12 The tridimensional structure of the GD of PrPC was determined by nuclear 
magnetic resonance.13-17 This is arranged in three α-helices corresponding to residues 144–154, 
173–194, and 200–228, interspersed with an antiparallel β-pleated sheet formed by β-strands at 
residues 128–131 and 161–164. A single disulfide bond is found between cysteine residues 179 and 
214 (in human numbering).16,18 
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Figure 4. A) Schematic representation of the primary structure of PrPC and its post-translational 
modifications. S-S, single disulfide bridge; MA, membrane anchor region; the proteinase K (PK) resistant 
core of PrPSc is depicted in grey; the approximate cutting site within PrPSc is indicated by the arrow. The size 
of the PK resistant fragment is variable, being cut at various positions between amino acids 78-102. B) 
Schematic representation of the PrPC showing its GPI membrane anchor, the two N-linked glycans and the 
octapeptide repeats that bind metal ions. 
 
Full-length PrPC is found in non-, mono-, or diglycosylated forms, corresponding to the variable 
occupancy of residues Asn-181 and Asn-197 in human PrPC and Asn-180 and Asn-196 in mice.19,20 
 
2.3. Physiological processes involving PrPC 
Although PrPC is highly expressed in the CNS, its biological role is not well established.21 Several 
processes are influenced by PrPC. Neurite outgrowth, including growth of axons and dendrites, are 
reduced in neurons lacking PrPC.22 Other processes include neuronal survival, neurite outgrowth, 
synapse formation, maintenance, and function, and maintenance of myelinated fibers (reviewed in 
21, see Figure 5). The prion protein has been considered to function as an antioxidant, a metal 
transporter, a cell adhesion molecule, and a signal transducer.23-25 Table 1 summarizes all the 
cellular processes in which PrPC is demonstrated to be involved.21 A possible role of PrPC as a 
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cellular receptor for the amyloid β-oligomers implicated in Alzheimer’s disease has been 
suggested,26 however, this remains controversial.27,28 
 
Figure 5. Physiological functions proposed for PrPC (Adapted from ref. 21). 
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Table 1. Cellular distribution and activities of PrPC in cell types in which known or putative functions have 
been described (Adapted from ref. 1). 
 
2.4. Structural conversion from PrPC to PrPSc 
There are two models to explain PrPC→PrPSc conformational conversion. 
The “template-directed refolding” hypothesis predicates an instructionist role for PrPSc on PrPC 
(Figure 6A). According to this model, a high energy barrier is preventing the conversion from PrPC 
to PrPSc, therefore the need of an exogenously introduced PrPSc molecule is necessary for the 
replication to start: PrPSc interacts with and converts an endogenous molecule of PrPC into a newly 
formed, β-sheet rich PrPSc isoform. The newly formed PrPSc molecule, in turn, can transform other 
endogenous PrPC molecules. This hypothesis is supported by several experiments. Transgenic 
mouse studies have provided genetic29 and biochemical30 evidence that the conversion of PrPC to 
PrPSc occurs through the formation of a PrPC/PrPSc complex. However, such a complex has never 
been isolated to purity. Nevertheless, the existence of such partially structured monomeric folding 
Cell type Process Function 
Neuron Neuritogenesis Adhesion, signalling 
 Synaptogenesis, 
polarization 
Signalling 
 Survival, trophic 
effects 
Anti-apoptotic 
  Pro-apoptotic 
 Copper binding Copper endocytosis 
  Copper homeostasis 
  SOD activity 
 Redox 
homeostasis 
Signalling 
Neural stem cells Neurogenesis Unknown 
 Differentiation Unknown 
Hematopoietic stem cells Long-term 
renewal 
Anti-apoptotic? Homing? 
T cells Activation Signalling? 
 Development Antioxidant 
Leukocytes Differentiation Unknown 
 Phagocytosis Unknown 
 Inflammatory 
response 
Homing 
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intermediate of the prion protein is also suggested by hydrogen-deuterium exchange31 and high-
pressure spectroscopy experiments.32 
Alternatively, the “seeded nucleation model” proposes that PrPSc exists in equilibrium with PrPC. 
PrPC and PrPSc are in a reversible thermodynamic equilibrium, which strongly favours the PrPC 
conformation. Only when several molecules of PrPSc are aggregated (into oligomeric or fibril-like 
seeds), the replication can start. In this case, the seed recruits other monomeric PrPSc molecules and 
stabilizes them. The fragmentation of the aggregates increases the number of seeds that can actively 
recruit new PrPSc molecules, thus accelerating the replication process, the prion accumulation, and 
finally giving rise to the disease. In a nondisease state, such equilibrium would be shifted toward the 
PrPC conformation, such that only small amounts of PrPSc would coexist with PrPC. But in this case, 
PrPSc could not represent the infectious agent, since it would be ubiquitous. According to this 
hypothesis, the infectious agent would consist of a highly ordered aggregate of PrPSc molecules. The 
aggregated state would be an intrinsic property of infectivity. Monomeric PrPSc would be 
innocuous, but it might be prone to incorporation into nascent PrPSc aggregates (Figure 6B). 
 
Figure 6. Theoretical models for the formation of PrPSc amyloid from PrPC 
 
These two models cannot be considered mutually exclusive, and indeed the different aetiology of 
prion diseases (genetic, infective or sporadic) can be fitted in both  
the models:33-35 
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• In inherited disease, genetic mutation of the PRNP gene may destabilize the tertiary 
structure of PrPC promoting the spontaneous conversion to PrPSc, or these mutations can lower the 
energy barrier from PrPC to PrPSc, thus facilitating and accelerating PrPSc aggregation.  
• In infective disease, the ingestion of an already preformed PrPSc aggregate can directly 
convert endogenous PrPC molecules, or act as an already preformed PrPSc-aggregate and recruit 
PrPSc molecules.  
• In sporadic form, biochemical modifications (whose characteristics are at present unknown) 
of PrPC, or other environmental aspects, can perturb PrPC tertiary structure and then favour the 
conversion into PrPSc. However, if and what biochemical and environmental mechanisms are at the 
basis of sporadic form is yet to be clarified. 
 
2.5. PrPSc models 
Extensive characterization of PrPSc was undertaken in an attempt to understand its structural 
features. A key problem with much of the literature on PrPSc fold is that there are considerable 
disagreements.36 As shown in Figure 7, several different structural models of PrPSc have been 
promulgated based on a range of theoretical and experimental data. The three most prominent are: 
• A β-helix based on fiber diffraction and electron microscopy studies of brain-derived PrPSc.37,38 
The first of these models, guided by digital reconstitution of two-dimensional, p3 symmetry crystals 
sometimes observed in PrPSc isolates, postulates a β-helical structure.37 By threading a portion of the 
prion protein sequence through a known β-helical fold, it was proposed that residues ∼90-175 form 
left-handed β-helices, which associate into trimers, with two preserved α-helices (see Figure 7A). 
• A parallel and in-register β-sheet model proposed from spin labelling and electron paramagnetic 
resonance studies of recombinant misfolded prion protein.39 Structural data suggest that prion 
protein conversion to amyloid fibrils involves major refolding of the entire α-helical domain. 
Indeed, two recent studies, using hydrogen-deuterium exchange40 and site-directed spin labelling,39 
indicate that the β-sheet core of the human prion protein amyloid maps to the C-terminal part of PrP 
encompassing residues ∼160/ 170-220. Distance information obtained from spin labelling studies 
demonstrated that residues within this core region form single-molecule layers that stack on top of 
one another with parallel in-register alignment of β-strands (see Figure 7B). 
• An extension of the native β-sheet has been proposed from immunologic studies41 and molecular 
dynamics simulations at low pH.42 This model depicts a trimeric oligomer, which is postulated to 
stack in a spiral-like manner to form higher-order protofibrillar aggregates. Here, the amyloid β-
core consists of a three-β-strand sheet (residues 116-119, 129-132, and 160-164, respectively), and 
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an isolated strand (residues 135-140), with all three α-helices retaining their native monomeric 
conformation (see Figure 7C) 
The lack of agreement on even basic features of the PrPSc fold may derive in part from an inherent 
heterogeneity in misfolding. Although there is one native structure for PrPC, there may be multiple 
misfolded structures, each arising from a local energetic minimum in the conformation space of 
PrPSc. Environmental conditions, including the presence of PrPSc seeds of a particular subtype, and 
variation in the PrP primary sequence may steer PrPC molecules into one of a range of misfolded 
geometries. 
 
 
Figure 7. Structural models of PrPSc and/or PrP amyloid fibrils. A) β-Helical model, where residues ∼90-175 
are shown to form left-handed β-helices that associate into trimers, leaving the most C-terminal helices of 
monomeric PrPC intact.37 B) Parallel and in-register β-structure model determined experimentally for 
recombinant PrP amyloid fibrils.40 In this model, residues, 160-220, form the PrP amyloid core with tight 
interdigitation of side chains. Individual monomers stack to form single-molecule layers so that the same 
residues are perfectly aligned. C) Spiral model depicting the amyloid core as being comprised of a three 
stranded β-sheet and an isolated β-strand, with complete retention of all three native α-helices.42 
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Since each study described above employed a different methodology for generating PrPSc, it is 
possible that each one accessed a different stable misfolded conformer, some or all of which may be 
relevant in disease. This is supported by the well-known existence of strains in prion disease with 
distinct neuropathological features.43 In this sense the search for the PrPSc structure, while not futile, 
may yield a plurality of valid possibilities rather than a single definitive answer.36 
However, the divergent models provided by structural studies may ultimately reflect the 
conformational variability of PrP aggregates associated with TSE disorders where, in addition to the 
existence of multiple prion strains, there are indications that neurotoxic and infectious PrP are 
distinct conformational species. Clearly, despite recent advances, major discoveries in structural 
biology of mammalian prions are still to be made.44 Understanding molecular mechanism of protein 
misfolding and aggregation is useful to aim to inhibit or reverse the conformational changes as a 
therapy to protein conformational disease.   
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2.6. Prion neuroinvasion in humans 
Neuroinvasion typically begins upon ingestion of the PrPSc agent. Strong evidence suggests that the 
feeding of BSE-contaminated meat and bone meal to livestock was responsible for the outbreak of 
BSE in England, and subsequent consumption of diseased cattle by humans is believed to be 
responsible for the emergence of vCJD.2,45 After oral infection PrPSc can be found in Peyer’s 
patches in the gut and is followed by prion propagation to splenic lymphoid tissue and/or in gut-
associated lymphoid tissue (GALT; including tonsil), resulting in prion transport by splenic 
innervation to the brainstem and spinal cord.44,46  
The route of infection is defined by three phases (see Figure 8): 
• The first phase is, after ingestion, the invasion of the gut-associated lymphoid tissues 
(GALT). Onodera et al. discovered that neonatal Fc receptor (nFcR), which contributes to the 
uptake of maternal antibodies into the intestine, plays a role in PrPSc incorporation into the 
intestine.47 Another study demonstrated that the iron binding protein ferritin forms a complex with a 
fragment PrPSc to enhance the transport of PrPSc in an intestinal endothelial cell model, suggesting a 
role for ferritin in transport of infected prion protein across the intestine.48  
•  After incubation in lymphoid tissue such as the GALT and spleen, the PrPSc spreads to the 
CNS via the enteric nervous system. This invasion occurs in the retrograde direction along efferent 
fibers of both sympathetic and parasympathetic nerves 
• The final phase is the infection of the spinal cord and brain leading to characteristic 
spongiform degeneration and astroglial activation.  
 
Figure 8. Schematic representation of the potential mechanism of neuroinvasion in transmissible spongiform 
encephalopathies. (i) Initial uptake of the PrPSc agent from the intestinal lumen has been proposed to occur 
through a number of alternative mechanisms. (ii) After amplification of the TSE agent in lymphoid tissue 
such as the GALT and spleen, invasion of the central nervous system is believed to proceed through 
sympathetic and parasympathetic nerves. 
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2.7. Cellular Mechanisms of Prion Toxicity  
Once PrPSc fibrils are formed, the cellular pathological mechanisms by which prion exert their 
neurotoxic effects are still under debate.49 Three mechanisms have been proposed as possible 
mechanisms of neurotoxicity.5 These are: 
• “loss-of-function” mechanism 
It remains possible that prion neurodegeneration is related, at least in part, to “loss of function” of 
PrPC. But the “loss-of-function” mechanism appears to be incompatible with the observation that 
PRNP0/0 mice are relatively normal and do not display features of prion disease (see Figure 9).50 In 
potential agreement with this hypothesis, Brown and co-workers have shown that lack of PrP 
expression results in neuronal sensitivity to oxidative stress; however, this did not lead to 
neurodegeneration.51 
• “gain of function” mechanism 
Based on this hypothesis, a toxic, possibly infectious, product is produced during the process of 
conversion of PrPC to PrPSc. The protein aggregates, accumulated in the nervous system, are 
presumed to possess a novel neurotoxic activity that is independent of the normal, physiological 
function of the parent protein (Figure 9). For example, PrPSc aggregates may block axonal 
transport, interfere with synaptic transmission, or physically damage cellular membranes.8,21 In 
contrast, other studies show that accumulation of PrPSc within PrPC-expressing tissue grafted into 
the brains of PRNP0/0 mice does not damage the neighbouring PrPC-null tissue10 and the 
accumulation of PrPSc in glial cells around PrPC-null neurons does not induce cell death in the 
knockout neurons, arguing against a direct toxic effect of PrPSc per se. 
• “subversion-of-function” mechanism 
Another possibility is that PrPSc subverts or modifies the normal function of PrPC (the “subversion 
of function”), rather than causing a complete loss of PrPC function (Figure 9). For example, the 
PrPC activity might be altered after binding to PrPSc (or to another pathogenic intermediate), such 
that a neurotoxic rather than a neuroprotective stimulus is delivered.  
However, the physiological function(s) of PrPC is (are) still unknown, and a lot of controversies 
surrounding the several proposed functions of PrPC are still under debate. 
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Figure 9. The “gain of function” mechanism: PrPSc possesses a novel neurotoxic activity that is independent 
of the normal function of PrPC. The “Loss of function” mechanism: PrPC possesses a normal, physiological 
activity, in this case neuroprotection, that is lost upon conversion to PrPSc. The “Subversion-of-function” 
mechanism: the normal neuroprotective activity of PrPC is subverted by binding to PrPSc (Adapted from ref. 
52) 
  
 22 
2.8. Therapeutic approaches to prion diseases  
Based on knowledge of prion cell biology, several strategies for intervention can be envisioned that 
target different stages of prion biogenesis and PrPSc formation and aggregation. Main strategies for 
intervention are shown in Figure 10.53 These can be accomplished by: 
• eliminating PrPC 
• stabilizing PrPC 
o preventing PrPC unfolding  
o interfering with binding of PrPC to PrPSc 
• enhancing PrPSc clearance. 
 
Several studies indicate that the removal of PrPC is important for subsequent conversion into PrPSc. 
Therefore, targeting PrPC synthesis or cell surface localization or enhancing endocytosis of PrPC 
might be viable anti-prion strategies.  
PrPC and PrPSc are localized in specific regions of the cellular membrane, called lipid rafts, rich in 
cholesterol and sphingolipids. Lipid rafts have been proposed as potential targets for PrPSc 
formation.54 Therefore, potential compounds, which change membrane cholesterol levels altering 
PrPC and PrPSc distribution, might block prion conversion. The statins, lovastatin and squalestatin, 
are inhibitors of two enzymes of the cholesterol synthetic pathway. Treatment of the cells with 
lovastatin55 or squalestatin56 prevents the accumulation of PrPSc in infected cell lines. The antifungal 
drug Amphotericin B and its analogue, MS-8209, reduce PrPSc formation in cell culture by 
intercalation into and disruption of the cell membrane. Amphotericin B has also been shown to 
prolong incubation time of prion diseases in hamster.57 
Among the compounds tested for inhibition of PrPSc accumulation in cultured cells, suramin was 
found effective.58 Suramin treatment prevents the cell surface localization of PrPC by binding to 
PrPC and inducing its intracellular aggregation in the Golgi compartment.58 The PrPSc aggregates are 
PK sensitive, and can be easily degraded by the cells and do not accumulate.58 Polyanionic 
compounds like pentosan polysulfate (PPS) or dextran sulfate (DS) enhance endocytosis of PrPC, 
thereby leading to its depletion at the cell surface.59  
 
A major focus of drug discovery efforts has been the PrP conversion reaction. Many compounds 
have been shown to prevent the conversion by directly binding PrPC and blocking the conversion 
 23 
from PrPC to PrPSc. An increasing number of studies have found that binders of PrPC are potent 
antiprion compounds in scrapie-infected cell lines.60-67 
PrPSc was the most obvious target for anti-prion therapeutics because it can easily be quantified by 
Western-blotting of proteinase K-resistant PrPSc. Currently cell-based assays are the most used 
method for screening anti-PrPSc compounds, although it is difficult to define the compound’s mode 
of action in a “black box” cell assay where only the reduction of PrPSc levels is monitored. Thus, a 
compound shown to reduce PrPSc in cells may act by slowing formation or accelerating the 
breakdown of PrPSc and this may be through on- or off-target effects. The assumption that 
neurodegeneration derives from direct toxicity of PrPSc has been increasingly challenged, not least 
by the recognition of sub-clinical prion infection, the state in which animals can have high levels of 
infectivity without clinical disease. Targeting PrPSc may appear to be the most logical approach, but 
such targeting may be not enough to block the disease progression.68 Phuan et al. have shown by 
using a chemical proteomics approach, that bis-acridine compounds, potent antiprion compounds,69 
interact selectively with PrPSc.70 
Another strategy is devoted to enhance the cellular clearance of PrPSc (Figure 10). Treatment with 
the polycationic lipopolyamine DOSPA decreased the PrPSc levels in the cells by enhancing PrPSc 
clearance and blocking de novo formation of PrPSc.71  
Further discussion of this issue can be found in ref. 35,46,68,72,73 
 
Figure 10. Potential therapeutic targets to block prion propagation.  
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2.9. Prion diseases: a multifactorial disorder 
Nowadays the protein-only theory has become widely accepted and therefore current therapeutic 
strategies are primarily aimed at preventing conversion of PrPC → PrPSc. Targeting PrPC has the 
potential to remove the substrate for the pathogenesis and is applicable regardless of the disease 
aetiology. While this hypothesis stands for in vitro conversion of PrPC to PrPSc, the mechanism 
underlying in vivo conversion, although not fully elucidated yet, seems to be more complex, 
possibly involving other pathways.74 During the last decade, it has been gradually accepted that 
prion disease pathogenesis involves a complex array of processes operating simultaneously and 
synergistically.74  
These include: 
(i) protein aggregation;8,75  
(ii) oxidative stress (OS) accompanied by lipid and protein oxidation;76-80  
(iii) reduced levels of potent free-radical scavenger, such as polyunsaturated fatty acids,  
 α-tocopherol, and glutathione;76-80  
(iv) unbalance of metal ions;80,81 
(v) brain inflammation with activation of astrocytes and microglia.82 
 
2.9.1. Oxidative stress (OS) 
There is growing evidence that OS, induced by ROS or free radicals, plays key role in the 
pathogenesis of neurodegenerative disorders including prion diseases.83 Cell culture experiments 
reveal that cerebellar cells lacking PrPC are more sensitive to OS and undergo cell death more 
readily than wild-type cells.78,84,85 Choi et al. have reported that the levels of malondialdehyde 
(MDA) and heme oxygenase-1, which are oxidative stress markers, and the generating rate of free 
radicals, especially superoxide anion (O2-), were significantly increased in the brains of scrapie-
infected mice (Figure 11).83,85-87 Increased lipid peroxidation and reduced activities of cytochrome c 
oxidase and ATPase were observed in mitochondria from scrapie-infected animals.88 In the 
mitochondria of infected mice, level of oxidized form of glutathione and calcium content were 
markedly increased, whereas mitochondrial membrane potential and energy metabolites (ATP/ADP 
ratio) were decreased.89 Milhavet et al. demonstrated that prion-infected hypothalamic neuronal 
GT1 cells displayed a higher sensitivity to induced oxidative stress over non-infected cells.78 In 
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addition, the infected cells presented an increased lipid peroxidation and signs of apoptosis 
associated with a dramatic reduction in the activities of the glutathione-dependent and superoxide 
dismutase antioxidant systems.78 There are many evidences that PrPC itself has a oxidative stress-
protective activity.90,91 Oxidative stress can therefore be the consequence of an increased production 
of reactive species or a decrease in the capacity of antioxidant defences to remove them, or both.79 
Some studies have confirmed the role of PrPC in the OS by pointing out deregulations of nitric 
oxide metabolism. Ovadia et al. reported a decrease in neuronal nitric oxide synthase (NOS) 
activity associated with an abnormal folding of the enzyme in infected neuroblastoma cell cultures 
and in brain extracts of infected mice.92 In a latter study, the same group confirmed these results in 
the brain of PRNP0/0 mice and suggested that PrPC could play a role in the cellular targeting of the 
neuronal NOS.93  
 
Figure 11. Conversion of PrPC into PrPSc increases the sensitivity of neuronal cells to oxidative stress through 
one or several of the following mechanisms: i) Cu metabolism could be modified influencing the redox status 
or the oxidative enzyme systems of the cell; ii) the production of ROS could be directly modified through, for 
example, the SOD-like activity of PrPC; and iii) the conversion could act on protein regulation and/or 
transcription factors involved in response to oxidative stress. Moreover, prion infection activates glia and 
microglial cells triggering the death of already impaired neurons. 
 
2.9.2. Metal ions and prion diseases 
PrPC may function as a metal binding protein because divalent cations such as Cu2+, Zn2+ and Mn2+ 
can bind to octapeptide repeat sequences in the N-terminus.12,81 Since the binding of these metals to 
the octapeptide has been proposed to influence both structural and functional properties of prion 
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proteins, alterations in transition metal levels might alter the course of the disease.81,94-96 In the 
following, we are going to depict the critical function of metal ions in the physiopathology of prion 
diseases.94  
 
2.9.2.1. Copper and PrPC 
PrPC binds five Cu2+ ions under physiological conditions. Four copper-binding sites are within the 
octapeptide repeat sequence Pro-His-Gly-Gly-Gly-Trp-Gly-Gln, between residues 61 and 91 of 
PrPC (human numbering). This region binds copper ions with femto- and nanomolar affinity, and 
other metal ions like Ni2+, Zn2+, and Mn2+ with affinities lower by at least three orders of magnitude. 
The fifth copper-binding domain is between residues 91 and 111 and is coordinated by histidine 
residues at positions 96 and 111 of the PrPC sequence.97 Also, the high conservation of the metal 
binding regions among various mammalian species indicates a relation between copper and the 
prion protein.98  
The functional role of PrPC in copper uptake from the extracellular milieu has been studied in 
cultured cells and mouse models.81 In mouse neuroblastoma cells, extracellular copper ions 
stimulate the endocytosis of PrPC, supporting the idea that PrPC may bind and deliver extracellular 
copper ions to endocytic compartments. Deletion of the octapeptide repeat region or mutation of His 
residues within this region abolishes copper uptake by PrPC, emphasizing the role of this region in 
copper binding.80  
Recently, studies have been undertaken to verify the concentrations of metals in mice affected by 
prion disease. Interestingly, changes of copper levels were observed in samples of brain, liver and 
blood. In particular, a reduction of Cu2+ was found in the brain, while significant increases were 
observed in the liver.91,99 This evidence suggests a role of the prion protein as a possible copper 
transporter in the CNS. Additional studies have shown that over-expression of PrPC resulted in 
higher binding of copper in the membrane fraction, which further supports the possible notion that 
PrPC is a copper transporter.98 
Not only does the PrPC seem to act as a copper transporter, but studies have also shown PrPC has 
superoxide dismutase (SOD)-like activity, enabling its effective functioning as an antioxidant in 
CNS.100 Studies with recombinant prion protein showed proper protein folding in the presence of 
copper, endowing PrPC with antioxidant capacities. Further, two atoms of copper bound to PrPC 
were sufficient for SOD-like activity.12 However, although the SOD-like function of PrPC was 
demonstrated in vitro,101 other studies have disproved the possibility that prion protein functions as 
a SOD-like protein in vivo.102  
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Together, these studies suggest a role for PrPC in cellular copper uptake and transport,103 
maintenance of physiologically safe copper concentrations at the synapse, upregulation of PrPC 
expression in response to copper,80,95 although authentication of these interactions in functional 
assays is incomplete. 
 
2.9.2.2. Manganese and PrPC 
An interesting feature of PrPC is that it does not only bind copper specifically, but also manganese. 
A study undertaken on a mouse scrapie model has demonstrated changes in the levels of copper and 
manganese in the brain of scrapie-infected mice prior to the onset of clinical symptoms.100,104 
Brazier et al. have used isothermal titration calorimetry to identify the manganese binding sites in 
mPrPC. This study indicated that the main manganese binding site is associated with His-95 in the 
so-called “fifth site” normally associated with copper binding.105 
2.9.2.3. Iron and PrPC  
The interaction of PrPC with iron deserves a special note, because iron is required for optimal 
neuronal growth, and, like copper, is considered a toxin because of its ability to exist in two 
oxidation states, ferric (Fe3+) and ferrous (Fe2+).80 Free iron can catalyze the conversion of hydrogen 
peroxide to reactive hydroxyl radicals by the Fenton reaction, resulting in oxidative damage. 
Furthermore, iron-dependent lipid peroxidation generates potentially toxic peroxyl/alkoxyl radicals, 
and iron is known to convert neutral catechols to neurotoxic intermediates, leading to neurotoxicity. 
Because imbalance of cellular iron homeostasis can result in the generation of ROS, the transport of 
iron in and out of the cells is tightly regulated. Within cells, iron is present in ferritin, which serves 
the general function of intracellular iron sequestration, detoxification, and storage. Free iron does 
not exist in physiological systems, and is always found bound to various iron transporting proteins 
and iron bound enzymes. More recently, Fernaeus et al. have demonstrated that iron regulation is 
disturbed in scrapie infected mouse neuroblastoma cells.106,107 More recently Singh et al. have 
suggested a functional role for PrPC in cellular iron uptake and transport.108-110 
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3. Computational studies of ligand/target complexes 
 when the targets lack a deep binding cavity 
 
Standard molecular docking protocols (MDPs, Figure 12) allow predicting the three dimensional 
structure of macromolecular complexes as well as their binding affinity at a low computational 
cost.1-3 These protocols require information about the structure of the target (Protein, DNA, RNA) 
and the ligand (small organic molecule) as well as the presumable interfacing region between them.1 
They are based on a step-wise process. First, a proper search algorithm (see Section 4.2) generates 
various configurations of the ligand within the binding site of the target. In the second step, each 
configuration is evaluated and ranked according to an energy function (see Section 4.3). These 
energy functions are usually based on effective potentials that are empirically trained to reproduce 
experimental binding affinities of validated training data sets of target-ligand complexes. This 
simplicity makes standard MDPs computationally cheap. It allows them to be used as a tool for 
virtual drug screening. In fact, these methods are routinely used in early stages of drug discovery to 
pre-screen large datasets of compounds. Thus, a remarkable decrease in the number of compounds 
to be synthesized and tested experimentally in the subsequent stages is achieved. In spite of these 
successes, there are still many important cases for which MDPs are challenged. These include the 
prediction of the poses of transition metal and/or alkylating drugs, of ligands causing large 
structural changes, and of ligands not binding to specific pockets. More important, solvation effects 
are not taken into account in these approaches.4,5 Free energy simulations may be then used to 
investigate the molecular association process and to predict binding affinity. Here we propose an 
enhanced molecular docking protocol (EMD in Figure 12) that extends MDPs with free energy 
simulations in explicit solvent to predict the structure and energetics of ligands binding to protein 
surfaces. Different classes of computational methods can be used.6,7 These include among the 
others: Thermodynamic Integration,10 MM/PBSA and MM/GBSA,11 Adaptive Bias Force 
Steering,12 Linear Interaction Energy,50 Steered Dynamics,14,15 Metadynamics,8,53 Umbrella 
Sampling.54 We use the metadynamics8,9 along with MDP to predict ligand binding poses onto 
protein surfaces for which a specific binding pocket is not defined. Such method treats explicitly the 
conformational flexibility of the receptor and also takes into account water solvation of the system. 
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Figure 12. Molecular Docking Protocols (MDPs) are used to guess putative ligand binding regions on target 
surfaces, based on structural information on the two separated moieties. Structural information on the target 
may come from NMR or X-ray studies and, in some cases, also from molecular simulation. Ligand may be 
docked on a putative binding site. Cluster analysis is used to group MD conformers and/or ligand/target 
adducts into representative structures. In the Enhanced Molecular Docking (EMD) approach, MD simulations 
may be used to relax the structures and to investigate the role of hydration. Enhanced sampling simulation 
techniques in explicit solvent (here metadynamics) allow to explore the ligand binding space and to predict 
free energy of binding. 
 
Four colleagues of Statistical and Biological Physics Sector (International School for Advanced 
Studies, SISSA/ISAS) carried out this work.  
I, together with Dr. A. Kranjc, studied the structure of the ligand, performed molecular docking 
calculations and cluster analysis. 
Dr. G. Rossetti performed molecular dynamic simulations and cluster analysis. 
Dr. X. Biarnes performed metadynamics. 
We together compared the computational results with experimental data.  
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3.1. Compound 1  
We focus on a small organic molecule able to bind to hPrPC, which can interfere with its conversion 
to the pathogenic form PrPSc. The ligand 1 is a symmetric molecule composed by two pyrrolidine 
rings connected by acetamides to a diphenylmethane core. 
1 (Figure 13) has been shown to significantly inhibit the PrPSc production in the neuronal mouse 
cells chronically infected with the Fukuoka-1 strain at 10 µM.18 The effect of the compound was 
dose-dependent, and by repeating the experiment Kuwata et al. established that the effective 
concentration for 50% reduction of PrPSc in scrapie-infected GT cells EC50≈ 1.35 µM.18 Treatment 
of infected mice with 1 showed slightly but significantly extension of the survival time.18  
To identify the putative sites for interaction of 1 with PrP, Kuwata et al. have analyzed the chemical 
shift perturbation of 1H-15N heteronuclear single quantum coherence NMR spectra of a uniformly 
15N-labeled PrP. A comparison of the spectra revealed that several cross peaks (corresponding to 
N159, V189, T192, K194, and E196) shifted significantly upon the addition of 1. Binding of 1 to 
PrPC was confirmed by the surface plasmon resonance (SPR), and its dissociation constant was 
estimated to be 3.9 ± 0.2 µM.18 
 
 
Figure 13. Chemical structure of 1  
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3.2. Compound 1 and mPrPC  
The reported chemical shifts perturbations of mPrPC induced by 1 binding affect most significantly 
amino acid residues on one side of the protein surface (Asn159 at α1- β2 loop, Lys194 at α2, 
Glu196, Thr199 at α2-α3 loop and Val210 at α3). In addition, Val189 and Thr192, located on the 
other side of the PrP surface, are also perturbed (Figure 14 and Table 2). This suggests that 
multiple binding sites may be present. Despite this, an ad hoc model of the 1-mPrPC adduct, 
constructed by docking and energy minimization exhibited a single binding mode of 1 connecting 
Asn159 and Glu196, nevertheless such single binding mode could not explain the contacts with 
Val189, Thr192.18 
 
Table 2. NMR chemical shift changes (δ) upon 1 binding to the mPrPC 
 
 
 
 
 
Figure 14. Residues involved in the interactions with 1. 
δ >0.9 ppm 0.5ppm< δ <0.9 ppm 
Asn159 Glu196 
Lys194 Arg156 
Val189 Val210 
Thr192 Thr199 
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Subsequent quantum-mechanical studies, based on this model, pointed out that these two residues, 
along with Gln160 and Lys194, are important for the binding. However, such single binding mode 
was not consistent with the presence of the contacts between the ligand and Val189, Thr192 and 
Thr199.19 Given the lack of deep binding pockets along the protein structure of PrPC, it is 
reasonable to assume that 1 will not bind specifically to a single site. This hypothesis was also 
encouraged from NMR data, which enables several residues located on distant regions of PrPC 
surface interacting with 1 to be identified.18  
Here we have applied our EMD protocol to provide: i) structural model of the adduct 1-PrPC; ii) 
affinity constant to be compared to experimental data. The EMD protocol emerges therefore as a 
useful approach to investigate ligands sticking on protein surfaces. 
 
3.3. Compound 1 and hPrPC  
Compounds 1 was studied by Kuwata et al. with murine cell lines expressing mPrPC.18 We are 
interested to ligands binding hPrPC because we focused our drug discovery project to the human 
cases. The sequence similarity is as high as 98%, and the root-mean-square difference (RMSD) of 
the backbone between the molecular dynamics (MD) structures of hPrPC (PDB code: 1HJM) is the 
same (0.26 (0.02 nm) as that between the NMR structures of hPrPC and mPrPC (PDB code: 1AG2) 
(0.27 nm). Therefore, significant changes of the structure on passing from the mPrPC to the hPrPC 
are not expected. For this reason, we applied our EMD protocol to study the interaction between 
ligand 1 and hPrPC.   
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3.4. Computational methods 
Structure of the ligand and Identification of Protonation States 
Titration curves calculated by the ChemAxon softwaree suggested that in aqueous solution at 
pH=7.4, molecule 1 is present in two protonation states (neutral, 10 and monoprotonated, 1+) while 
at pH=4.5 it exists in the diprotonated form (12+) (Figure 15). This method was used because it has 
been proved to be reliable: in a pKa calculation for 1000 molecules, less than 0.5 % turned out to 
differ by more than 0.5 pH unit from the experimental value. Before docking, all the three 
protomers underwent geometry optimization at the B3LYP/6-31G** level of theory by means of the 
Gaussian03 software (g03).20 
 
Figure 15. A) Acid-Base equilibrium of 1. B) Titration curve of 1 calculated by the ChemAxon software 
(www.chemaxon.com). At the pH of the Kd measurements, 1 is present in neutral (10) and monoprotonated 
(1+) states. At the pH of the NMR measurements, it exists also in diprotonated (12+) form. These two pH 
ranges are highlighted in the figure. 
 
                                                      
e www.chemaxon.org 
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Target structure – Molecular Dynamics – Cluster Analysis 
The NMR structure of hPrPC C-terminal GD resolved at pH 7 (residues 125-228, PDB ID: 1HJM) is 
used in this study. Protonation states were assigned by the web server H++f assuming pH 7.4.  
The protein was inserted into a cubic box of water molecules, ensuring that the solvent shell would 
extend for at least 0.8 nm around the system. Three sodium counterions were added to neutralize the 
system. The AMBER99 force field21 was used for the protein. Sodium ions were modeled with the 
AMBER-adapted 13Åqvist potential. The TIP3P model was used to describe the water molecules.22 
The system was minimized by imposing harmonic position restraints of 1000 kJ·mol-1·nm-2 on the 
solute atoms, allowing the equilibration of the solvent without distorting the solute structure. After 
an energy minimization of the entire system without harmonic restraints, the temperature was 
gradually increased from 0 K to 298 K in 12 steps. In each step, the temperature was increased by 
25 K in 100 ps of MD.  
Constant temperature-pressure (T=298 K, P=1 bar) 20-ns dynamics were then performed through 
the Nosé-Hoover23,24 thermostat and Andersen-Parrinello-Rahman25 barostat coupling schemes. 
Periodic boundary conditions were applied. The final simulation box equilibrated at around 6.69 x 
6.69 x 6.69 nm. Long-range electrostatic interactions were treated with the particle mesh Ewald 
(PME) 26,27 method, using a grid with a spacing of 0.12 nm combined with a fourth-order B-spline 
interpolation to compute the potential and forces in between grid points. The cutoff radius for the 
Lenard-Jones interactions as well as for the real part of PME calculations was set to 0.9 nm. The 
pair list was updated every 2 steps, and the LINCS algorithm28 was used to constrain all bond 
lengths involving hydrogen atoms which allows for a time step of 2 fs. The MD trajectory of the 
protein alone was clustered with the Gromos method29 and as result 20 different conformations were 
obtained, which were used along with the NMR structure for docking of compound 1. 
Docking procedure – Cluster Analysis 
The optimized structures of compound 1 (10, 1+ and 12+) were docked to the NMR structure of hPrPC and to 
its 20 different conformations obtained by the cluster analysis of the MD trajectory.  
The GOLD 3.130,31 and Autodock 3.0.532,33 programs were used for docking. In GOLD, the docking region 
was defined as a sphere of 3.5 nm radius around His187, so that the whole protein was screened. The 
ChemScore (CS)34 and GoldScore (GS)35 scoring functions were used for ranking. For each protomer and 
scoring function, 100 docking runs were performed. 
In Autodock, a Lamarckian genetic search algorithm was used to identify low-energy binding sites and 
orientations of compound 1 protomers. Binding modes were ranked by the scoring function implemented in 
                                                      
f http://biophysics.cs.vt.edu/ 
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Autodock. A grid map of 12.6 nm x 12.6 nm x 12.6 nm dimensions was centered to the center of mass of the 
protein, with the point grid spacing set to 0.0475 nm. Gasteiger atom charges were assigned to the protein 
atoms using AutoDockTools. Water molecules were excluded from the protein before docking. 100 randomly 
seeded docking runs were performed for each protomer. 
The binding poses were identified by AClAP 1.0 clustering procedure.36 
In the Chapter 4, I will discuss Docking method and Cluster Analysis in more details. 
Hydration and thermal stability of 1-hPrPC adducts 
10-ns MD simulations of the adducts (hPrPC-10, hPrPC-1+ and hPrPC-12+) allowed for a proper 
hydration of the system and for identification of collective motions that may be essential for PrPC-
ligand interactions. The protomers were bound to the binding site I (BS I). The simulation protocol 
was the same as for the free protein. For the three ligands, the gaff force field was used.37 The 
atomic restrained electrostatic potential (RESP) charges38,39 were calculated by using the resp 
module of AMBER after geometry optimization and electrostatic potential calculations of each 
protomer at the B3LYP/6-31G** level of theory by means of the g03 software.20  
Dissociation free energy calculations 
The dissociation free energies of 10, 1+ and 12+ were calculated using metadynamics8,40-43 in its bias-
exchange variant40-43 as a function of collective variables (CVs), which should be relevant for 
describing the dissociation process. CVs used in this work are: (i) the distance between the center of 
mass of the ligand and the center of mass of the protein binding site; (ii) the number of polar 
contacts between the ligand and one portion of the protein BS I; (iii) the number of polar contacts 
between the ligand and the other portion of the protein BS I; (iv) the number of water bridge 
contacts between the ligand and the protein BS I; (v) the RMSD difference of the system with 
respect to an equilibrated MD structure taken from the previous Section; (vi) the RMSD fluctuation 
of the residues defining the protein BS I. The choice of these CVs was based on previous ligand-
target interaction metadynamics studies as well as by observations based on the former MD 
simulations.40-43 
The calculations do not require in principle the previous knowledge of the protein-ligand adduct 
structure. However, for computational efficiency we exploit the fact that all the target regions 
detected from NMR are in the close proximity of BS I. Therefore, here we explored only this 
region. 
Six independent metadynamics simulations were run in parallel. Each replica was biased by 
different one-dimensional time-dependent potentials, which were built as a function of each of the 
collective variables defined above. Exchanges among replicas were attempted every 10 ps using a 
metropolis acceptance criterion.44 
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Similar set-up was shown to improve the sampling of the configurational space and the convergence 
of the results.40-43 
At the end of the different replica simulations, the explored phase space, in terms of the six 
collective variables used in this study, was clustered using the gromos method.29The clustering 
radius for each collective variable was set to 0.1 nm, 0.2, 0.4, 2.5, 0.05 nm, 0.02 nm, respectively. 
The free energy corresponding to each cluster was then reconstructed from the populations of 
clusters observed during the simulations. The free energy value was corrected by the corresponding 
bias potentials acting on that cluster as in a usual weighted histogram analysis. 
Details on metadynamics can be found in references: 8,9,40,44-46. 
Two reference states of the ligand-protein system, bound and unbound, needed to be defined to 
provide the corresponding dissociation free energy value. The bound state was considered as the 
lowest free energy cluster. The unbound state was considered to be a cluster showing no contacts 
with the BS I (lowest values of CVs ii and iii) and at the same time with a higher RMSD with 
respect to the initial docked structure (highest value of CV v). Given the size of the simulation box 
the ligand is not fully detached from the protein in its unbound state. Therefore, the residual 
dissociation energy of the unbound state was roughly estimated in implicit solvent using an adaptive 
Poisson Boltzmann solver.40-43 It was estimated as the difference in solvation energy of the complex 
minus the solvation energy of each component plus the intermolecular Coulomb interaction. The 
standard free energy of dissociation was obtained by applying the following relationship: ∆!! =   ∆! − !"×!" ! , where ΔG is the total dissociation free energy as a result of our 
simulation, R is the molar constant, and [L] is the concentration of the ligand in our simulation box 
(i.e. 5.5 mM, corresponding to 1 molecule in 6.693 nm3). The standard free energy is related to the 
dissociation equilibrium constant (Kd) by ∆! =   −!"×ln  (!!).  
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3.5. Results and Discussion 
In this study, we focus on the binding of compound 1 (Figure 13) to the surface of hPrPC. Two 
different conditions are considered: at neutral pH, where experimental affinity has been measured 
and at acidic pH, where NMR chemical shift perturbations have been obtained to identify the key 
residues involved in binding.  
We use the computational protocol summarized in Figure 12:  
(i) Identification of ligand protonation state at different pH.  
(ii) Use of MDPs to provide a first guess of putative binding poses. 
(iii) Use of MD simulations to relax the adduct structures in aqueous solution (step 1 in EMD). 
(iv) Use of metadynamics to predict: 
• the energetics of binding of 1 to hPrPC 
• the binding poses of the compound to hPrPC 
 
3.5.1. Protonation state of 1  
The tertiary nitrogen atoms in the pyrrolidine rings of 1 can exist in different protonation states: 
deprotonated, monoprotonated or diprotonated (Figure 15). At pH=7.4 where the Kd has been 
measured, approximate pKa calculations (www.chemaxon.org) suggest that, in water, 1 exists in 
both the neutral form (10) and the monoprotonated form (1+) (Figure 15). In the latter, one of the 
two pyrrolidine nitrogen atoms is protonated. 
At pH=4.5 where the NMR experiments were performed, the pKa calculations indicate a mainly 
diprotonated state (12+, with both pyrrolidine nitrogen atoms protonated), as well as a small amount 
of 1+. The calculated concentration of 10 in bulk water is very low (Figure 15). However, ligand-
protein binding does not occur in pure water and the electrostatic field of the protein should be 
taken into account. Indeed, simple electrostatic potential calculations show an increase of the 
positive charge density in the putative binding region of the protein defined by the NMR contacts 
(Figure 16). This suggests that the protein environment there will favour the accumulation of 
neutral 10. Therefore, binding poses involving the neutral form should be considered even at acidic 
pH. Based on these analyses, we performed calculations on all of the three protomers. 
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Figure 16. Figure Electrostatic potential generated by hPrPC at different experimental conditions. Left: NMR 
measurements conditions (pH=4); Right: Affinity measurements conditions (pH=7). Red volume represents 
the regions at -1.2 eV; Blue volume represents the regions at +1.2 eV. Center: Residues involved in 1 binding 
to the prion protein (in licorice), as emerging from chemical shift changes. 
 
3.5.2. Use of MDPs to provide a first guess of putative binding regions 
The three protomers were docked to the hPrPC NMR structure and 20 conformers obtained from the 
20-ns MD simulations of the protein in aqueous solution. Three putative BSs I, II and III were 
identified (Figure 17). BS I is defined by the α2 helix and the loop connecting β2 and helix α1. BS 
II consists of the α2-α3 helices. BS III is defined by the α3 helix, the N-terminal of α2 helix, and the 
loop between α1 helix and β1 sheet. Only BS I contains the residues that show chemical shift 
changes upon binding of compound 1 and it is closer to all the other residues involved in the 
binding. It was therefore the only one selected for the subsequent free energy studies. 
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Figure 17. Three different binding regions (I, II, and III shown in blue, red, and yellow, respectively), as 
obtained after MDP procedures. Orange spheres represent compound 1 binding aminoacids defined by the 
NMR chemical shift study. The figure shows hPrPC. 
 
 
3.5.3. Use of MD simulations to relax the structure in aqueous solution 
The adducts for each of the three protomers docked at BS I underwent 10 ns of MD calculations in 
aqueous solution. The ligands maintained completely (1+ and 12+) or partially (10) the pose 
identified in the docking. Most importantly, the structural determinants of the three protomers 
turned out to be consistent with most of the ligand-protein contacts identified by NMR (see Table 
2). However, the ligand-protein contacts with Val189, Thr192, Thr199 and Val210 could not be 
predicted by MDP. A simpler docking approach, combined with energy minimization of protomer 
10 obtained similar results to our findings (Figure 3 in Kuwata et al. 2007).9,47-49 
 
3.5.4.  Free energy calculations were then used to explore the ligand binding space in explicit 
solvent 
These simulations allowed to identify alternative binding poses for each protomer of the ligand and 
to predict the dissociation free energy. The free energy simulations were performed as a function of 
6 collective variables that took into account rearrangements of the ligand and protein, hydrogen 
bond contacts and water bridges. These variables have been already used to characterize ligand-
target molecular recognition processes using the metadynamics approach.18 
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3.5.4.1. hPrPC-10 complex.  
In the lowest free energy cluster identified by the metadynamics calculations, 10 is located in the 
wide cleft formed by helices α1, α2 and α3 (10.B1 in Figure 18), similarly to the model proposed by 
Kuwata et al. for mPrPC.18 In the global minimum, 10 is located in the wide cleft formed by helices 
α1, α2 and α3 (10.B1 in Figure 18), similarly to the model proposed by Kuwata et al. for mPrPC.18 
The contacts 10 forms with the hPrPC are consistent with the reported chemical shift changes on 
Glu196, upon 1 binding (Table 2), as well as with a recent quantum chemical study. They are also 
consistent with chemical shift changes on Arg156, Thr199, and Val210 upon 1 binding (Table 2). 
The phenyl groups of 10 form a π-cation interaction with Arg156 and a water-mediated H-bond is 
present between Thr199 and the pyrrolidine nitrogen (N1; Figure 18). The pyrrolidine ring forms 
hydrophobic interactions with Val210 (as well as with Pro158, Thr183). The hPrPC-10 complex is 
further stabilized with a direct H-bond between Thr190 and the carbonyl group of 10 (O2; Figure 
18). 
 
Figure 18. Three dimensional structures of hPrPC in complex with 10. These structures correspond to the 
bound-states free energy minima (10.B1), as calculated with the metadynamics method. 
 
The unbound state of hPrPC-10 system corresponds to a conformation in which the ligand has no 
contact with the protein. The conformation of Lys194 changes upon ligand dissociation (Figure 
19). This is consistent with the significant chemical shift change reported for this residue.  
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Figure 19. Ramachandran plot of residue Lys194 for the 10 adduct: Crosses indicate the conformation of the 
residue when the ligand is bound, and empty squares when the ligand is not bound. 
 
Smaller conformational changes were also observed for other residues in the α2-α3 loop (res. 195-
199). These rearrangements were not observed with the MD calculations, possibly because they are 
induced during the ligand binding process simulated here. 
The unbound state of hPrPC-10 is 5.5 kcal/mol ± 0.9 higher in energy with respect to the global 
minimum. The ligand is not completely detached from the protein, although 10 is already separated 
by 5 layers of water molecules between the two moieties. The remaining free energy for complete 
dissociation was estimated to be –0.7 kcal/mol by means of the Poisson-Boltzmann equation. Thus, 
we estimated the dissociation free energy to be 4.7 kcal/mol in our simulation conditions. 
Considering also the concentration of the species in the simulation box, the standard dissociation 
free energy is estimated to be 7.8 kcal/mol. This is in very good agreement with the experimental 
value of 7.5 kcal/mol (corresponding to Kd = 3.9 ± 0.2 µM) reported by Kuwata et al.18 
 
3.5.4.2. hPrPC-1+ complex 
Four different stable binding poses of 1+ were identified on hPrPC surface (Figure 20). In the global 
minimum, 1+ lays along the loop connecting helices α2 and α3 (1+.B1 in Figure 20). It forms a 
remarkable hydrophobic interaction with Thr199, consistent with the chemical shift changes 
reported for this residue.18 The amidic nitrogen atoms of 1+ (N3 and N4; In Figure 20) are H-
bonded to Thr201 and Asn197, respectively. This induces a subtle conformational change of the 
Glu196 and Asn197 backbone upon ligand binding which may be the cause of the chemical shift 
displacement reported experimentally for Glu196. Additionally, the neutral pyrrolidine ring of 1+ is 
accommodated by the hydrophobic cleft formed by Ile184, Thr188, Phe198, Val203 and Met206, 
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which further stabilizes the complex. No water-mediated interactions were observed between 1+ and 
hPrPC. 
With the corrections described above, the dissociation free hPrPC-1+ complex (11+.B1 in Figure 20) 
and the corresponding unbound state, with the corrections described above, turns out to be 8.6 
kcal/mol. This is similar to that predicted for 10 and in good agreement with experimental data. 
 
Figure 20. Three dimensional structures of hPrPC in complex with 1+. These structures correspond to the 
bound-state free energy minima (1+.B1-B4), as calculated with the metadynamics method. 
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3.5.4.3. hPrPC-12+ complex  
Five different stable binding poses of 12+ were identified on hPrPC surface (Figure 21). In the most 
stable conformation, 12+ binds yet in another position of hPrPC, laying along helix α2 (12+.B1 in 
Figure 21). Half part of 12+ is in close contact with hPrPC surface in the cleft formed by Val189, 
Thr192 and Thr193. Indeed, these positions were reported to interact directly with the ligand 
according to NMR experiments (Table 2). Two layers of water molecules are present between the 
protein surface and the rest of the molecule, presumably due to the presence of Lys185. In the other 
accessible poses, 12+ covers different regions of the protein surface (Figure 21). The interaction 
with Lys194 is conserved in the majority of the poses. This result is consistent with the chemical-
shift changes of this residue upon ligand binding. The dissociation free energy of 12+ was not 
calculated, as this protomer is not present at the conditions in which the Kd was measured.  
 
Figure 21. Three dimensional structures of hPrPC in complex with 12+. These structures correspond to the 
bound-state free energy minima (12+.B1-B5), as calculated with the metadynamics method.  
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3.6. Conclusion 
Our proposed EMD protocol was applied to identify the hPrPC sites where 1, in its different 
protonation states (0, +1, +2, see Figure 15), preferably binds. This protocol combines standard 
MDP with metadynamics, see Figure 12. As in any MDP, MD simulations were used initially to 
relax the protein structure in aqueous solution. Secondly, representative PrPC structures were 
selected by statistical analysis of the MD simulation. Standard docking calculations were then used 
to dock the ligand 1 on these protein structures, providing a first guess of putative binding regions. 
MDP was not sufficient to explain all distant contacts reported by NMR.18 Successively, 
metadynamics was used to simulate the 1 binding process from solution to PrPC surface. These 
simulations allowed us to identify alternative binding poses of 1 onto hPrPC surface and also to 
predict the binding affinity. These predictions were comparable to experimental data obtained via 
NMR chemical shift perturbations and affinity measurements. We observed a multiple binding site 
pattern of 1 complementing that proposed by Kuwata et al.18 Taken together, these provide a 
structural basis to explain all experimental NMR-contacts (see Figure 22).  
 
Figure 22. (A) Superimposition of 10 (yellow), 1+ (red) and 12+ (blue) binding poses. (B) The residues of 
mPrPC experimentally found to be involved in binding are highlighted in orange bars. 
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This result was not predictable a priori and could only be obtained when MDPs are extended with 
enhanced sampling simulations. This example represents a step forward to identify the binding of 
small organic molecules that to cavity-less proteins, in which water-mediated interactions become 
important and the ligand can bind at the same time in multiple sites of the protein surface. We 
conclude that our approach is a useful tool to predict poses and affinity of ligands binding to 
proteins with fibrillation properties. 
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4. Computational methods: molecular docking and 
 cluster analysis 
 
Computational molecular docking is a research technique for predicting whether one molecule will 
bind to a target, usually protein. Ligand is a small molecule – compared to a protein, which is a 
macromolecule. When binding to a protein, the ligand changes the conformation of the larger 
molecule, thereby affecting the protein operation. In protein-ligand docking the goal is to predict the 
position and orientation of a ligand when it is bound to a protein receptor or enzyme. The initial 
situation is such where the structure of the inspected protein and the ligand are known. Because of 
the excess of possible conformations due to huge number of degrees of freedom in large systems 
such as macromolecules, all possible conformations cannot be compared. The problem must be 
somehow limited. Simplifying the model can reduce the need for computational power. Of course, 
the active site, where the protein-ligand interactions occur, must be modeled as precisely as possible 
but the further regions of the macromolecule can be modeled less precisely because of their 
interaction with the active region being much weaker. 
Molecular docking is a computational tool and represents a crucial component of many drug 
discovery projects, from hit identification to lead optimization and beyond, such as structure-based 
design and virtual screening techniques.1 It is widely used to predict binding modes and select 
putative ligands for a biological target.2 The docking methodology was pioneered during the early 
1980s and remains a current and highly active area of research, thanks also to its short time and low 
computational cost.3 
In particular, it is a multi-step process in which each step introduces one or more additional degrees 
of complexity. Initially, the process begins with the application of algorithms that sample the 
several degrees of conformational freedom of small molecules “posing” them in the binding site. 
The algorithms are complemented by scoring functions that are designed to describe the biological 
activity through the evaluation of interactions between the ligand and the potential target as well as 
the entropic cost of the ligand conformation. 
Some of these scoring functions adopted for molecular docking try to estimate the free energy of 
binding of the ligand-target complex.4 Unfortunately, this estimation is not always reliable because 
of the high error associated to it. However, the molecular docking represents a useful technique in 
the computer-aided drug design and discovery context towards delicate issues such as the 
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identification of molecular features that are responsible for specific biological recognition and/or 
the prediction of chemical modifications to improve potency of ligands. 
Both these programs adopt genetic algorithms5 to generate the single poses of ligands into the 
binding site of protein target, which are evaluated by their appropriate scoring functions. 
Molecular docking is a computational procedure that predicts binding mode of a ligand in its target 
protein. This is achieved by minimizing a scoring function, which describes the interactions 
between ligand and target with respect to the atomic positions of the two moieties. In the following 
paragraph I will explain these issues. 
In this work, GOLD 3.0.16 and AutoDock 4.07,8 programs were used to predict ligand-protein 
interactions.   
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4.1. Algorithms in molecular docking 
Several algorithms are used in molecular docking programs to obtain the pose of ligand in the 
binding site of protein.6,9 In general, the docking problem is the search for the minimum of a 
function that depends on a large number of degrees of freedom, namely the position and the 
geometrical arrangement of ligand (its conformation) and of its target. 
The algorithms adopted in molecular docking can be divided in three types of searches: systematic, 
stochastic and deterministic; some algorithms combine more than one of these approaches. 
Systematic algorithms explore a grid of values for each degree of freedom considered, in a 
combinatorial way. As the number of degrees of freedom increases, the number of evaluations 
needed increases rapidly and termination criteria are inserted to prevent the algorithm from 
sampling space that is known to lead to the wrong solution. Stochastic search algorithms make 
random changes on the degrees of freedom of the system. To improve convergence, multiple 
independent runs are performed. In deterministic searches, the initial state determines the move that 
can be made to generate the next state, which generally has the same or a lower energy than the 
initial state. 
 
4.2. Genetic Algorithms (GAs) 
The Genetic Algorithms (GAs) belong the class of stochastic algorithms and are based on the 
language of natural genetics and evolutionary biology. GAs are computer programs that mimic the 
process of evolution by manipulating a collection of n data structures called chromosomes. Indeed, 
using genetic operations they search for possible conformations of ligands.5,9  
The quality of results depends on the starting genes, the number of evolutionary events and the 
scoring function adopted to select the most favourable conformers. Firstly, the GA generates an 
initial population as set of chromosomes (conformations of ligands randomly chosen and 
determined into the binding pocket). The chromosomes are defined by one or more strings of genes 
(variables), that can assume binary, integer or real values corresponding to: i) ligand translation (x, 
y, z coordinates of the center of mass); ii) ligand orientation (rotation angles); iii) ligand 
conformation (torsion angle for each rotatable bond). The population undergoes to a fitness 
evaluation of ligand-protein complex: each chromosome is associated to a score based on a function 
that approximately estimates the binding free energy/fitness. Starting from an initial population of 
chromosomes (parents), randomly generated and subsequently evaluated on the basis of specific 
scoring function, the GA repeatedly applies the three genetic operators, such as reproduction, 
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crossover and mutation, to obtain a new population of chromosomes (children) that replace the 
least-fit members of the population. 
• reproduction represents the selection process of the fittest members scored of a population 
that will survive in the next generation; 
• crossover combines chromosomes by performing a one or two-point crossing on the parent 
strings resulting in the children ones (as higher the number of crossover points is, more information 
is exchanged between the parent strings); 
• mutation randomly modifies one o more gene(s) to give the offspring chromosomes. 
Thus, in contrast with the only reproduction operator, crossover and mutation allow the exploration 
of the conformational space through the introduction of children chromosomes to be submitted to a 
new cycle of genetic operations. The whole cycle is repeated until some generations are defined 
and/or until some conditions (i.e. RMSD, ΔG) are satisfied.  
GOLD uses an island-based genetic algorithm search strategy and includes rotational flexibility for 
selected receptor hydrogen along with full ligand flexibility. AutoDock 7,8 uses a genetic algorithm 
as a global optimizer combined with energy minimization as a local search method. The ligand is 
flexible, while the receptor is rigid. 
 
4.2.1. Genetic algorithm in GOLD 
GOLD employs a so-called island-based genetic algorithm. This means that not only one large 
population of chromosomes (described in the previous section) is manipulated, but also several sub-
populations (i.e. islands) are considered and individual chromosomes can migrate among them. This 
feature improves the efficiency of search. In addition, information concerning H-bonds between the 
ligand and the protein target is also encoded in the chromosome. The H-bonds are matched with a 
least squares fitting protocol to maximize the number of inter-molecular ones. A population of 
potential solutions (in this case, possible docking poses of ligand) is set up at random. Each member 
of the population is encoded as a chromosome which contains information on: i) the mapping of 
ligand H-bounded atoms onto complementary protein ones; ii) mapping of hydrophobic points on 
the ligand onto protein ones; conformation around flexible ligand bonds and protein OH-groups. 
Each chromosome is assigned a fitness score based on its predicted binding affinity and the 
chromosomes within the population are ranked according to fitness. The population of 
chromosomes is iteratively optimized.10 
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4.2.2. Genetic algorithm in Autodock 
The AutoDock adopts a GA in which it is implemented a local search method, initially proposed by 
Solis and Wets,11 that allows to minimize the scoring function of selected individuals. The 
optimized atomic coordinates (phenotype) are stored back in the chromosome (genotype). Then, the 
new chromosome enters into a new iteration of genetic operators employed by GA. Given this 
transfer of information from phenotype to genotype this algorithm is called Lamarckian genetic 
algorithm (LGA).7 
 
4.3. Scoring Functions 
The evaluation and ranking of predicted ligand conformations is a crucial aspect of molecular 
docking. Thus, the design of reliable scoring functions is of fundamental importance. Scoring 
functions implemented in docking programs make various assumptions and simplifications in the 
evaluation of modeled complexes and do not fully account for a number of physical phenomena that 
determine molecular recognition for example, entropic effects. Essentially, three types or classes of 
scoring functions are currently applied: force-field-based, empirical and knowledge-based scoring 
functions. 
Molecular mechanics force fields usually quantify the sum of two energies, the receptor–ligand 
interaction energy and internal ligand energy (such as steric strain induced by binding). Most force-
field scoring functions only consider a single protein conformation, which makes it possible to omit 
the calculation of internal protein energy, which greatly simplifies scoring. Various force-field 
scoring functions are based on different force field parameter sets. 
The empirical scoring functions are fit to reproduce experimental data, such as binding energies 
and/or conformations, as a sum of several parameterized functions. The design of these scoring 
functions is based on the idea that binding energies can be approximated by a sum of individual 
uncorrelated terms. The coefficients of the various terms are obtained from regression analysis 
using experimentally determined binding energies and, potentially, X-ray structural information. 
There are also the scoring functions knowledge-based, which are designed to reproduce 
experimental structures rather than binding energies. In knowledge-based functions, ligand–protein 
complexes are modeled using relatively simple atomic interaction-pair potentials. A number of 
atom-type interactions are defined depending on their molecular environment. In common with 
empirical methods, knowledge-based scoring functions attempt to implicitly capture binding effects 
that are difficult to model explicitly. 
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Here, we revise the scoring functions implemented in the programs used in the thesis: GoldScore 
and ChemScore for GOLD, and the empirical scoring function from AutoDock 
4.3.1. GoldScore (GS) in GOLD 
GS is a force-field-based scoring function and, in particular, it is defined the weighted sum of the 
following components (scores: S; see the equation reported below): the energies from H-bonds 
(Shb_ext) and van der Waals interactions (Svdw_ext) of complex protein/ligand, and the ones from 
internal van der Waals (Svdw_int) and torsional strain (Stors_int) of ligand.6,12  
!" = !!!_!"# +   !!"#_!"# +   !!"#$_!"# + !!"#_!"#   
Optionally, a fifth component describing the intra-molecular hydrogen bond (Shb_ext) energy of 
ligand may be added. GS is defined as a fitness function, where every single component is coupled 
to some give coefficients. These were empirically determined on the basis of adjustments performed 
to best reproduce a series of known crystallographic ligand/protein complexes. 
The H-bond term considers the difference between the interactions of protein and ligand in the 
complex and free in water, thus accounting for desolvation effect: initially the donor (d) and the 
acceptor (a) are considered in solution and, then, on coming together (da) water (w) is stripped off. 
Therefore, the H-bond energy Eij between a donor i and an acceptor j between the ligand and the 
protein is composed by the following terms: 
!!" =   !!" +   !!!    − (  !!" +   !!"   ) 
 
The interaction energies for each donor and acceptor types are pre-calculated with quantum 
mechanics and molecular mechanics approaches for a set of model fragments. For all the poses of 
ligand generated, the possible combinations of donors i and acceptors j between the ligand and the 
protein’s atoms surrounding it are evaluated and a weight wij between 0 and 1 is assigned to each 
bond on the basis of both the distance between donor and acceptor and the angle formed by donor, 
H atom and acceptor: 
 )()(tan iHjangleijcedisij
www +=
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The distance dLP is between the donor and the acceptor’s lone pair. In default implementation of 
GOLD, dmax varies linearly from 4.0 Å at the first iterations to 1.5 Å after 75000 iterations to let 
only close-contacts H-bond contribute to GS fitness value of the final solutions. Similarly, is the 
angle between the donor, the H atom and the acceptor lone pair. The H-bond energy term in the 
scoring function is then given by the sum of all individual H-bond energies, multiplied by their 
weights: 
!!! = !!"  !" !!" 
The internal energy contribution is considered in GS function only when it is positive to avoid a 
lower minimization of the internal energy of ligand than of the one of reference conformation. It is 
the sum of the steric and torsional energies ligand: the steric energy is described by a sum over all 
the atoms i ≠ j, separated by a distance dij, in the ligand of a 6-12 potential term: 
!!" = !!!"!" −    !!!"!  
whereas the torsional one, associated with four consecutively bonded atoms I, j, k, l, is given by: 
 
!!"#$ = 12   !!"#$    1 +    !!"#$!!"#$ cos !!"#$   !!"#$  
where ωijkl is the torsional angle, nijkl the periodicity and Vijkl the barrier of rotation. 
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The term Evdw describes the close-contact interaction energy and it is calculated as the sum over all 
pairs of atoms i and j, respectively from ligand and protein, which are distanced between them less 
than 1.5 times the sum of their van der Waals radii. A 4-8 potential is used to describe this 
interaction: 
!!" = !!!"! −    !!!"!  
where dij is the distance between two atoms. If Eij > sEij,min, a linear cut-off is applied to switch off 
this interaction, Eij,min being the minimum of Eij and s being a scaling factor whose value increases 
logarithmically during the run in order to encourage the close contacts. A and B were chosen with 
the aim at reproducing the minimum of the standard 12-6 potential of the form. The 4-8 potential is 
preferred because it is softer and allows the algorithm to easily form close-contacts with the protein. 
 
4.3.2. ChemScore in GOLD 
ChemScore was derived empirically from a set of 82 protein-ligand complexes for which measured 
binding affinities were available.13,14 Unlike GoldScore, ChemScore was trained by regression 
against measured affinity data. ChemScore estimates the total free energy change that occurs on 
ligand binding as a sum of different components:  
ChemScore = c0 + chbond Shbond + cmetal Smetal + clipo Slipo+ crot Hrot + Pclash + cinternal Pinternal + 
(ccovalentPcovalent + Pconstraint) 
where chbond, cmetal, and clipo are scores for hydrogen bonding, acceptor-metal, and lipophilic 
interactions, respectively. Hrot is a score representing the loss of conformational entropy of the 
ligand upon binding to the protein. The “c” terms are coefficients derived from a multiple linear 
regression analysis on a training set of 82 protein–ligand complexes from the PDB 
Shbond The summation function for hydrogen bond strengths is 
!!!"#$ = !(∆r!"  !" ,∆r!,∆r!)  !(∆α!",∆α!",∆α!") 
with ∆r!" =    r!" −   r!  and, ∆α!" =    α!" −   α! , where r!" is the H···A distance, and α!"the 
D-H···A angle for a given donor–acceptor pair. r! and α! are the ideal hydrogen-bond distance and 
angle, respectively. ∆r!,∆r!,∆α!",∆α!" are constants that control the deviation from the ideal 
hydrogen-bond distance and angle. 
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The hydrogen-bond term is computed as a sum over all possible acceptor-donor pairs such that one 
atom belongs to the protein and the other to the ligand. Each term in the summation is the product 
of three Gaussian-smoothed block functions. The purpose of the block functions is to reduce the 
contribution of a hydrogen bond according to how much its geometry deviates from (a) ideal H···A 
distance (where ‘H’ is the hydrogen atom linked to the donor atom (‘D’), ‘···’ the hydrogen bond, 
and ‘A’ the acceptor atom), (b) ideal D-H…A angle (where D-H is a covalent bond between donor 
and hydrogen atom), and (c) ideal directionality with respect to the acceptor atom. The maximum 
contribution of a given acceptor-donor pair to the summation is 1; this will occur if the pair forms a 
hydrogen bond of “ideal” geometry. 
The Shbond, Smetal, and Slipo terms all make use of a block function, B, of the following shape (see 
Panel A and B): 
A
 
B
 
C
 
 
In ChemScore the block function is convoluted with a Gaussian function (see panel C). 
Smetal The metal-binding term in ChemScore is computed as a sum over all possible metal-ion 
acceptor pairs, where the acceptor is an atom in the ligand that is capable of binding to a metal. It 
only has a distance dependency. 
Slipo The lipophilic term is defined in a similar way. 
!!"#$ = !(∆r!"  !" ,∆r!,∆r!)   
The summation here is over all pairs of lipophilic atoms in protein and ligand. r!" is the distance 
between protein and ligand atom for a given pair of lipophilic atoms. r!and r! are constants 
controlling the range of lipophilic interactions. Lipophilic atoms are defined as non-accepting 
sulphurs, non-polar carbon atoms and non-ionic chlorine, bromine and iodine atoms. 
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The final ChemScore fitness function contains terms such as clash penalty term (Hrot) and internal 
torsion term. 
Hrot estimates the flexibility penalty for molecules with frozen rotatable bonds: 
 
Nrot being the number of frozen rotatable bonds, and Pnl(r) and P’nl(r) the percentages of polar 
atoms on either side of the rotatable bond. 
Clashes between protein and ligand atoms and ligand internal torsional strain are accommodated by 
penalty terms (Pclash) in order to prevent poor geometries in docking. The clash penalty terms differ 
on the nature of the contact, whether it is a hydrogen-bonding contact, a metal-binding contact or 
neither of these. Covalent and constraint scores may also be included. 
4.3.3. Scoring function in Autodock 
In AutoDock7 the implemented scoring function is defined as an empirical binding free energy 
function: 
∆! =   ∆  !!"# !!"!!"!" −   !!"!!"!!,! +   ∆  !!!"#$ ! ! !!"!!"!" −   !!"!!"!"!,! +   ∆  !!"!#   !!   !!  !   !!"   !!"     !,!
+ ∆  !!"#   !!"# +   ∆  !!"#    !!   !!   + !!!!   !,!   ! !
!!"!!!!  
   
The summations are performed over all pairs of ligand atoms, i, and protein atoms, j, in addition to 
all pairs of atoms in the ligand separated by three or more bonds. rij is the distance between the 
atoms, φ is the H-bond angle, and qi is the electrostatic charge of atom i. All five ∆G terms on the 
right hand side are coefficients empirically determined using linear regression analysis from a set of 
thirty protein-ligand complexes with known binding constants. The first three terms are in vacuo 
interaction terms: Lennard/Jones 12-6 dispersion-repulsion term; a directional 12-10 hydrogen 
bonding term; screened Coulomb electrostatic potential. ∆Gtor is a measure of the unfavorable 
entropy of ligand binding due to the restriction of conformational degrees of freedom, and Ntor is the 
number of sp3 bonds in the ligand. The last term approximately accounts for the desolvation free 
energy upon ligand binding. For each atom in the ligand, fragmental volumes of surrounding 
Hrot =1+ 1!
1
Nrot
"
#
$
%
&
'
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protein atoms (Vj) are weighted by an exponential function and then summed, evaluating the 
percentage of volume around the ligand atom that is occupied by protein atoms. This percentage is 
then weighted by the atomic salvation parameter of the ligand atom (Si) to give the desolvation 
energy. 
4.4. Cluster Analysis 
AClAP implements a hierarchical agglomerative clustering algorithm.15,16 Hierarchical’’ means that 
clusters at a higher level are union of clusters at lower levels, while ‘‘agglomerative’’ means that 
clusters never break apart during the formation process. The global hierarchy can be represented by 
means of a dendrogram, a tree showing different clustering levels, spanning from 1 to n. RMSD is 
taken as a measure of conformation-to-conformation distance. Therefore, the clustering algorithm 
starts with n unitary clusters; at each step, the two closest clusters are merged, until only one cluster 
containing all the poses is reached.17 The way the inter-cluster distance is evaluated by the average 
linkage method. Once the hierarchical tree is built, KGS penalty function is used to define the best 
clustering level and to prune it. At the end for each cluster, the representative conformation is 
calculated.15,16 
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5. Design, synthesis and evaluation of three classes of 
 anti-prion compounds to attack prion diseases 
 on multiple fronts 
 
The multi target directed ligand (MTDL) theory is becoming an interesting approach in the 
drug discovery field, being particularly used to combat multifactorial diseases. For the last ten 
years, many research groups have been involved in designing and synthesizing MTDLs against 
cancer, depression, schizophrenia and neurodegenerative disorders. With the aim of exploiting 
for the first time this approach in prion diseases, we developed two series of MTDLs able to act 
as antioxidants and simultaneously slow down PrPSc aggregation (Chapters 6 and 7). 
Additionally, a compound with dual antiprion and metal chelator activity has been developed 
(Chapter 8). 
 
I designed and synthesized the developed compounds in the Medicinal Chemistry laboratory of 
Prof. M. L. Bolognesi (University of Bologna) whereas the biological experiments were performed 
by Dr. Hoang Ngoc Ai Tran in the Prion Biology Laboratory of Prof. G. Legname (Neurobiology 
Sector, International School for Advanced Studies, SISSA). 
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5.1. Introduction 
Prion diseases are lethal for both humans and animals. Although researchers have attempted for 
decades to develop effective therapeutics for the therapy of human and animal prion disorders, until 
now no drug has been available on the market for TSE treatment or cure.1-4 
The effectiveness of a potential antiprion drug is, in principle, tested by three systems: in vitro 
systems representing mainly scrapie propagating cells, in vivo systems representing scrapie-infected 
rodents or macaques, and finally clinical studies. Although a series of drug candidates demonstrated 
convincing effects in vitro and in vivo, all tested compounds failed to show significant effects in 
patients with prion diseases.5 As for other neurodegenerative disorders, the development of an 
effective antiprion compound is particularly challenging because the drug has to penetrate the 
blood–brain barrier.2-4 Thus, although several compounds were effective in cell culture systems, in 
many cases they lacked any effect in vivo because of their low penetration into the CNS.5  
Nowadays the protein-only theory has become widely accepted, and therefore current therapeutic 
strategies are primarily aimed at the development of molecules able to preventing conversion of 
PrPC to PrPSc at different levels of this multistage process.2-4 Targeting PrPSc may appear the most 
logical approach, but such targeting might have no effect on disease progression if PrPSc is a non-
pathological end-point. To note, there is increasing evidence that PrPSc in vivo is not directly 
neurotoxic, and there is a lack of correlation between PrPSc deposition and disease severity,6 
suggesting that the conversion of PrPC to PrPSc is the key event in prion pathogenesis, rather than 
the accumulation of PrPSc. Thus, targeting PrPC has the potential to eliminate the substrate (PrPSc) 
for the pathogenic conversion, and is applicable regardless of the disease etiology. While the 
protein-only hypothesis stands for in vitro conversion of PrPC to PrPSc, the mechanism underlying in 
vivo conversion, although not fully elucidated yet, seems to be more complex, possibly involving 
some molecular chaperones.2-4 Recently, it has been gradually accepted that prion disease 
pathogenesis involves a complex array of processes (protein aggregation; oxidative stress; 
unbalance of metal ions; brain inflammation) operating simultaneously and synergistically.7 Thus, 
the failures of drug candidates developed according to the traditional drug discovery paradigm 
“one-molecule-one target” and the current challenge of discovering an efficacious therapy are likely 
related to the multifactorial nature of these diseases. This is in line with what has been found in 
other neurodegenerative diseases, such as Alzheimer’s disease (AD).8 Against this backdrop, a 
polypharmacological approach consists in the concerted pharmacological intervention against 
multiple targets, and might show superior efficacy and safety towards complex neurological 
disorders. In this thesis this strategy has been applied for the first time to rationally design new 
ligands against prion diseases. 
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5.2. Multi-target directed ligand (MTDL) approach 
Drugs that modulate multiple targets simultaneously (polypharmacology) might have the potential 
to enhance efficacy or improve safety relative to drugs that address only a single target.9 Since lack 
of efficacy and poor safety are currently the main causes of failure of clinical candidates, it is not 
surprising that the multi-target drug discovery (MTDD) area is attracting increasing attention 
among drug discoverers.10 Several drugs currently on the market have been found to have activity at 
more than one target, but in most cases the multiple activities were not deliberately designed, but 
only discovered in retrospect. A recent trend in medicinal chemistry has been to rationally design 
ligands that act selectively on multiple targets (selectively nonselective drugs). These compounds 
have been named MTDLs to distinguish them from the historical multiple agents or so called 
“promiscuous drugs” that often have poor selectivity and off-target effects as result of a non-
rational design.11 Currently, there are three complementary polypharmacological approaches. The 
first involves combining two or more different drugs that have different therapeutic mechanisms. In 
fact, when a single drug is not sufficient to effectively treat a disease, a multiple-medication therapy 
(MMT) (also referred to as a “cocktail” or “combination of drugs”) may be used. However this 
approach might be disadvantageous for patients with compliance problems. A second approach 
might be the use of a multiple-compound medication (MCM) (also referred to as a “single-pill drug 
combination”), which implies the incorporation of different drugs into the same formulation in 
order to simplify dosing regimens and improve patient compliance. Finally, a third approach 
involves discovering single agents that are simultaneously capable of addressing two or more 
targets, i.e. MTDLs (Figure 23).9-12 Increasing numbers of MTDLs are being reported in the 
literature and have been successfully exploited in the fields of AD and similarly complex  
diseases.9-22 
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Figure 23. Therapeutic strategies: evolution of monotherapy (A) to therapy with different drugs forming a 
multiple-medication therapy (MMT) (B) or a multiple-compound medication (MCM) (C) or with a single 
drug molecule able to modulate multiple targets (D). Strategies depicted in (B), (C), and (D) should, in 
principle, produce the same therapeutic effect in treating a given disease. However, only (D) avoids the risk of 
drug-drug interactions that are possible with (B) and (C). 
 
Clearly, therapy with a MTDL (see Figure 23) would have intrinsic advantages over MMT or 
MCM.23 It would obviate the challenge of administering multiple single-drug entities, which could 
have altered bioavailability, pharmacokinetics, and metabolism. Indeed, if a single molecular 
species can show a complex ADMET profile, an MMT/MCM approach might be untenable. 
Furthermore, in terms of pharmacokinetic and ADMET optimization, the clinical development of a 
drug able to hit multiple targets should not, in principle, be different from the development of any 
other single lead molecule. It thus offers a much easier approach than MMT/MCM. More 
importantly, the risk of possible drug-drug interactions would be avoided and the therapeutic 
regimen greatly simplified in relation to MMT/MCM. All these considerations are of particular 
relevance, as one of the major contributions to the attrition rate in drug development continues to be 
the drug candidate’s pharmacokinetic profiling.24 There is, therefore, a strong indication that the 
development of drugs able to act at different levels of the neurotoxic cascade might disclose new 
opportunities for the treatment of major neurodegenerative diseases, for which an effective cure is 
an urgent need and an unmet goal (Figure 24).25 
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Figure 24. Pathways leading to the discovery of new medications: (A) Target-driven drug discovery 
approach, that is, the application of the current one-molecule-one-target paradigm. (B) MTDLs approach to 
drug discovery. A drug could recognize (in principle, with comparable affinities) different targets involved in 
the cascade of pathological events leading to a given disease. Adapted from Cavalli et al. 25 
 
However, the selection of the therapeutic targets (to seek either a single- or a multi-target-directed 
ligand) is one of the biggest challenges in designing new molecules for multifactorial 
neurodegenerative diseases. Clearly, MTDLs should target the most important pathophysiological 
processes. Obviously, better understanding of which targets are therapeutically relevant should shed 
light on the underlying causes of this diseases and may also help in the development of more 
efficacious drugs. However, more clues on the target selection come from the system biology 
approach which can help to identify targets for intervention.17,26 
The main criticism to MTDL drug discovery paradigm is that this approach is ambitious, because 
the rational design of MTDLs has to deal with the critical issues of affinity balancing and 
pharmacokinetics.11 However, as proof of principle, and to support the view that MTDLs are 
destined to become the mainstream of neurodegenerative diseases therapeutics in the next years, it 
could be useful to mention the successful case of ladostigil (TV-3326), an MTDL developed by 
Youdim and co-workers, which is currently in phase II clinical trials for AD.g 
 
                                                      
g http://clinicaltrials.gov/ct2/show/NCT01354691 
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5.3. Strategies for Designing MTDLs  
Basically, two conceptually different methods23 have been followed to generate MTDL hit 
compounds with which to commence a MTDD project. They are: 
• Screening approaches  
• Knowledge-based approaches 
The first approach involves the random screening of either diverse or focused compound libraries to 
different targets. The second one is the most common MTDL generation strategy reported in the 
literature, termed “framework combination”. Framework combination starts with two compounds, 
one of which binds with high selectivity to one of the targets and the other with high selectivity to 
the other target of interest. The goal is to combine both activities into a single molecule by 
integrating the frameworks (and the underlying pharmacophores) of the two selective molecules. 
MTDLs arising from framework combination can be viewed as linked, fused, or merged depending 
upon the degree to which the frameworks have been integrated (see Figure 25).9-12 
 
Figure 25. Framework combination is a knowledge-based approach to generate MTDLs. 
 
In linked MTDLs, the molecular frameworks are joined by linker groups that are not found in either 
of the selective ligands, and the different ends of the molecule are typically responsible for the 
activity at the different targets. A cleavable or non-cleavable linker might be used. The majority of 
reported examples of cleavable conjugates (termed “codrug”) contain an ester (or amide, disulfide) 
linker that is cleaved by plasma enzymes to release the two individual drugs that then act 
independently.27 The first clinically used codrug for the treatment of rheumatoid arthritis was 
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sulfasalazine (Salazopyrin), a derivative of mesalazine. It is a combination of sulfapyridine and 5-
amino salicylic acid coupled with an azo linkage. The linkage is broken down by the enzyme 
azoreductase.28 Currently the drug is used for the treatment of ulcerative colitis.29 Portoghese et al. 
reported heterodimeric conjugates containing delta-antagonist (naltrindole) and kappa-agonist (ICI-
199441) pharmacophores tethered by metabolic stable linkers.30,31 If the frameworks are in contact 
but there is neither a discernable linker nor much framework overlap, the MTDL can be viewed as 
fused. Finally, in merged MTDLs, the frameworks are overlapped by taking advantage of 
commonalities in the chemical structures of the starting compounds. Normally, medicinal chemists 
will aspire to maximize the degree of overlap in order to produce smaller and simpler molecules, 
which have a better chance of oral activity. It might be expected that an MTDL would be larger and 
more complex than single target ligands. Because larger and more flexible molecules have been 
associated with poorer PK profiles, optimizing the pharmacokinetics of the lead compound while 
retaining a balanced target profile is frequently the most challenging aspect of a MTDD project.9 
 
5.4. Polypharmacology in prion diseases 
Although a polypharmacological approach is still in its infancy in prion diseases, the MMT strategy 
has been already addressed. Indeed, drug combination (DC) strategy has been applied in numerous 
in vitro and in vivo approaches with the aim of exploiting synergistic effects. The several examples 
reported in Table 3 suggest that inhibition of prion replication can be effectively potentiated by DC 
treatment.   
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Table 3. Two-drug or three-drug combinations in prion diseases 
Two-drug combination Two prion aggregation inhibitors (quinacrine and 
desipramine) 
Ref. 35-37 
 Cholesterol ester modulators (everolimus, pioglitazone)  
+ prion aggregation inhibitors (chlorpromazine)  
Cholesterol ester modulators (everolimus, pioglitazone)  
+ prion aggregation inhibitor (quinacrine) 
Ref. 32 
 
 
Ref. 32 
 a heparan sulphate mimetic (pentosan polysulfate)  
+ ligand targeting PrPC (Fe(III)meso-tetra(4-
sulfonatophenyl)porphine) 
Ref. 34 
Three-drug combination Two prion aggregation inhibitors (quinacrine and 
desipramine)  
+ an inhibitor of cholesterol biosynthesis (simvastatin) 
Ref. 39 
 
As for MTDLs, the literature contains cases where the deliberate aim of creating an MTDL has not always 
been explicitly stated. Instead, the molecular hybridization strategy has been followed, leading, to chimeric 
molecules capable, in principle, of modulating multiple targets. The first anti-prion chimeric ligand, 
Quinpramine (4, Figure 26) was designed on the basis of in vitro synergistic anti-prion effects of drugs 
Quinacrine (2) and Imipramine (3). 4, obtained by linking 2 and 3 moieties through a piperazine ring, showed 
an improved anti-prion activity as much as 15-fold over 2 and 250-fold over 3.39,44 
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In the following sections, we will describe the fragments used to design MTDLs by exploiting a 
framework combination approach. Fragments can be divided in three categories: 
• Prion recognition motifs (PRMs); 
• Antioxidant fragments; 
• Metal ion chelator fragments.   
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5.5.  Privileged structures as “Prion-Recognition Motif” 
A privileged structure is a molecular scaffold able to provide potent and selective ligands for a 
range of different biological targets through the modification or insertion of particular functional 
groups. Privileged structures should possess good drug-like properties, which in turn should lead to 
more drug-like compounds. The concept of privileged structures was first introduced by Evans et al. 
in 198845 and was later updated by Patchett and Nargund.46 For nearly 20 years, privileged 
structures have represented an ideal source of core scaffolds and capping fragments for the design 
of combinatorial libraries directed at a broad spectrum of targets. Numerous privileged structure-
based libraries have proven to be extremely effective for the rapid discovery and optimization of 
potent and selective ligands for a wide variety of GPCRs,47 kinases, proteases and even PPIs.48  
Two heterocyclic motifs, namely quinoline and acridine, are particularly frequent in compounds 
with multiple and diverse biological activities and also active against prion diseases. For this reason 
they can be considered truly privileged structures (see Figure 27). 
 
Figure 27. Quinolines (A) and acridines (B) because of their recurrence in a broad variety of biologically 
active compounds that hit different pharmaceutical targets and pathways are truly privileged scaffolds. 
 
5.5.1. Quinolines and prion diseases  
Quinoline derivatives are promising antiprion drug candidates (Figure 28). Antimalarial drugs 5 
and 6 have been reported in several studies as effective antiprion compounds.49,50 Stimulated by the 
findings that the same compounds (i.e., 5 and 6) cured both prion and protozoan diseases, Korth and 
co-workers undertook to draw out the structure-activity relationships (SAR) of a series of antiprion 
and antimalarial quinolines.39 Interestingly, 7 displayed antiprion activity at nanomolar range in 
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scrapie-infected cells and inhibited P. falciparum growth at the same concentration, suggesting that 
some molecular targets of antiprion and antimalarial ligands might overlap.42 As in the antimalarial 
projects, bis-quinolines were also tested as inhibitors of PrPSc accumulation in cell cultures. Bis-
quinoline 8 inhibited prion fibril accumulation in scrapie-infected cells. Surface plasmon resonance 
(SPR) studies showed that 8 binds with high affinity to recombinant mouse PrP. In general, bis-
quinolines were more effective than quinolines in inhibiting prion fibril formation in vitro, but with 
marginal effectiveness in vivo.40 Interestingly, 8 is a highly specific copper chelator and also has a 
superoxide dismutase-like activity. It was Fukuuchi et al. who demonstrated that 8 decreases the 
total amount of PrP and PrP mRNA expression in prion-infected cells. These results suggest that 8 
may inhibit PrP biosynthesis and/or PrP transition to the cell surface and decrease the amount of 
substrate available for conversion to PrPSc.51 Fragment 9 inhibits the aggregation of Syrian hamster 
PrP (ShaPrP109-149, residues 109-149) significantly.52  
 
Figure 28. Quinoline derivatives for neurodegenerative diseases.  
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5.5.2.  Acridines and prion diseases  
Quinacrine (2, Figure 26) (EC50 = 0.3-0.5 µM) was used to treat malaria until more effective drugs 
replaced it. A renewed interest arose from its ability to inhibit prion formation, suggesting that it 
could offer an effective treatment for prion diseases.53 2 and several acridine derivatives were 
shown to block the infectious PrP isoform (PrPSc) formation in scrapie-infected cells.54 In a recent 
clinical trial (PRION-1), 2 was reasonably tolerated but did not significantly affect the clinical 
course of the disease.55 One explanation for the lack of benefit from 2 in this study was that 
adequate drug concentrations were not achieved in the CNS because 2 is known to be a substrate for 
P-glycoprotein multi-drug resistance (MDR) transporters. Moreover Ghaemmaghani et al. 
demonstrated by using MDR0/0 mice that 2 eliminates only a specific subset of PrPSc conformers, 
resulting in the survival of drug-resistant prion conformations. The results suggest that the failure of 
2 in vivo cannot be attributed solely to its pharmacokinetic properties.56 The quinacrine analogs (10-
11, see Figure 29), which have dialkylaminoalkyl side chains at 9-amino position, have been 
qualified by SPR as strong hPrPC binders.57 To overcome the limitations associated with the use of 2 
in prion diseases, several groups began research efforts aimed at identifying more potent analogs 
with a better pharmacokinetic profile. A focused library of variously substituted 9-aminoacridines 
was screened for bioactivity against accumulation of PrPSc.41 13 (see Figure 29, EC50 = 0.4 ± 0.1 
µM) showed a reduced cytotoxicity toward liver and kidney cells. SAR studies conducted by Cope 
et al. have shown that an electron-rich aromatic ring attached through an amine linker to the 
position para to the ring nitrogen is beneficial for both binding to PrPC and suppressing PrPSc 
accumulation. 13 demonstrated activity in the micromolar range (EC50 = 0.25 µM).41 A 9-
anilinoacridine 14, structurally related to 13, displayed a submicromolar EC50 value (0.06 µM) on 
ScN2a cell models, lower than that of 2 (EC50 = 0.23 µM).57 
 
 
Figure 29. Acridine derivatives for prion diseases. 
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Due to the propensity of PrPSc to assemble into multimeric forms, May et al. postulated that dimers 
of 2 could be more potent inhibitors of prion replication. They joined different tricyclic heterocycles 
through alkyl, polyamine and alkyl ether chains. Interestingly, antimalarial compound 15 (BiCappa) 
was shown to reduce PrPSc levels in ScN2a cells with an efficacy 10-fold greater than that of 2 (EC50 
= 0.30 µM).43 Another dimeric compound was developed by Korth and co-workers based on the 
enhanced effect of tricyclic antidepressant imipramine (3) in combination with 2. They thus 
synthesized the hybrid ligand Quinpramine (4, see Figure 26).39,44 
Considering the key role of a planar hydrophobic structure in perturbing PPIs in conformational 
diseases, and the wide activity of acridine and quinoline derivatives in prion diseases, it is 
conceivable that these motifs are privileged PRMs. 
 
5.6. Antioxidants used as antiprion compounds 
Studies on prion-infected cell and mouse models have provided useful information on the 
therapeutic potential of antioxidants.58 Although a clinically viable antioxidant that can alleviate 
prion disease–associated neurotoxicity is lacking, many observations argue that neutralizing 
oxidative stress may have therapeutic benefit in prion disease and provide the basis for future 
investigations in this area.4 In the following a list of antioxidants studied in prion diseases is 
reported. 
• Flupirtine has the exceptional ability to normalize intracellular glutathione levels 
and restore oxidative balance within the cell thereby combating accumulation of ROS and 
other free radicals A study published in 2004 reported some beneficial effects on cognitive 
function in patients with CJD.59 
• Curcumine is was shown to also be an efficient inhibitor of PrPSc propagation by 
interacting with PrP. Unfortunately, efforts to show in vivo efficacy of curcumin have so far 
failed.60,61 
• The nonpsychoactive Cannabis constituent cannabidiol, thanks to its multiple 
property (antioxidant, NMDA antagonist, regulator of microglial migration and activation) 
inhibited PrPSc accumulation in both mouse and sheep scrapie-infected cells.62  
• Vitamin E enhances survival of Prnp0/0 cells significantly more than of wild-type 
cells in a dose-dependent manner.63 
• Martin et al. demonstrated an up-regulation of Coenzyme Q (CoQ) dependent 
antioxidant systems in response to the increased oxidative stress induced by prion infection 
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in nervous tissue. Thus, they suggested to use CoQ related agents able to cross the blood–
brain barrier.64 
• Lipoic acid was administered together with other antioxidants to a patient affected 
by prion disesases, showing moderate therapeutic effects.65 
 
5.6.1. Selected Fragments with antioxidant properties 
Among the above mentioned antioxidants which showed potential against prion diseases, we 
focussed on Coenzyme Q (16) and lipoic acid (17), which may be useful to prevent or treat prion 
dementias.65 
5.6.1.1. 1,4-benzoquinones 
16 is an important endogenous lipophilic antioxidant found in all organisms. 16 (Figure 30) is 
composed of an isoprenoid tail joined to a BQ nucleus. 10 isoprene units form the tail. It is known 
to have a role in electron transport and proton transfer in mitochondrial and bacterial respiration 
(Figure 31). 16 is an electron acceptor molecule of the electron transport chain. Ubiquinone is the 
oxidized form of 16, while ubiquinol corresponds to a reduced form. When ubiquinone accepts a 
pair of electrons (along with a pair of hydrogen ions), it becomes ubiquinol, which is the “active” 
antiozidant form. 16 also a role in the prevention of mitochondrial dysfunction,66,67 apoptosis,68,69 
and oxidative damage.66,67 In neurodegenerative disorders, especially in aging and Alzheimer’s 
disease, levels of 16 are altered, suggesting a role in disease progression. In effect, 16 has been used 
as a therapeutic agent against certain neurodegenerative disorders.68,69  
The efficacy of 16 in the treatment of TSE neurodegenerative disorders should be improved by 
studying related agents able to cross the blood–brain barrier better than 16, because the brain 
penetration of 16 from a enriched diet or peritoneal inoculation has been described as very 
poor.67,70,71 As a further support to the potential of BQ derivatives against neurodegenerative 
processes, we should mention that 16 and different benzoquinone derivatives have been previously 
shown to modulate Alzheimer’s disease molecular targets, directly inhibiting Aβ aggregation.14,72 
 
Figure 30. Structure of Coenzime Q (16) 
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Figure 31. Redox Reactions of 16. 
 
Based on these findings, we decided to exploit a 2,5-bis-diamino-1,4-benzoquinone nucleus to 
design new antiprion agents. To note, in this structure, because of the resonance effect of the 
quinone ring, a hydrophobic and planar π system is generated, which is able in principle to bind 
amyloid and to perturb protein–protein interactions in the fibrillogenesis process.73; 
 
5.6.1.2. α−Lipoic acid  
Lipoic acid (17, see Figure 32) is known as a universal antioxidant.  
 
Figure 32. Structure of α-lipoic acid 
 
The reduced form of 17 (Figure 33) acts as an antioxidant by directly scavenging ROS, by reducing 
the oxidized form of other endogenous antioxidants, and by chelating transition metals, rendering 
such metals either redox inactive or facilanting their removal from the cell.74,75 
 
Figure 33. Oxidized and reduced lipoic acid. 
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17 is readily absorbed by diet, transported, taken up by cells, and reduced to dihydrolipoic acid in 
various tissues, including brain. It has been demonstrated that dihydrolipoic is an even more potent 
antioxidant than lipoic acid.  
All in all, we selected lipoic acid (17) for the following reasons: (i) the molecule is an endogenous 
antioxidant; (ii) well-tolerated in vivo; (iii) effective against fibril formation; (iv) chemically 
linkable to the amine group by amide bond formation. On this basis, 17 was proposed by us as a 
lead structure for designing MTDLs for neurodegeneration.74,75 
 
5.7. Metal chelators used as antiprion compounds 
As discussed in Chapter 1, chelation therapy has been proposed as a valuable therapeutic approach 
towards prion diseases.76 As an example, metal chelators shown to be effective are reported. 
• Chelation of copper with D-penicillamine, a drug used routinely for treating Wilson 
disease, decreased brain-copper content of prion-infected mice by 30% and prolonged the 
incubation period, supporting the idea that increased levels of brain copper promote 
diseases.77 
• Clioquinol is an antibiotic that binds to zinc, copper, and iron, and crosses the 
blood–brain barrier effectively. The use of Clioquinol in scrapie-infected hamsters increases 
the incubation time, suggesting a future potential for the use of this drug in humans.79  
• Chrysoidine, a chelating agent, is about 27 times more effective than quinacrine in 
ScNB cells.78 
Clioquinol or 5-chloro-7-iodo-8-hydroxyquinoline (18, Figure 34),79 was used in the past as an 
antibiotic for treating diarrhea and skin infection.80 Moreover, 18 81 inhibits metal-induced Aβ 
aggregation82 and reactive oxygen species generation in vitro and in AD transgenic mice.80 18 was 
thus studied in 2003 in a randomized, placebo-controlled, phase II clinical trial by Ritchie et al.87 
Because of toxic effects, clioquinol has been abandoned in favor of a successor compound, PBT2 
(19), which lacks the iodine atom.81 19 targets metal-induced aggregation of Aβ, but is more 
effective as a Zn/Cu ionophore and has greater BBB permeability than 18.83 8-Hydroxyquinoline 
compounds have also found application in Parkinson’s disease. Youdim and co-workers have 
discovered a novel multifunctional anti-Parkinsonian drug M-30 (20), which possesses iron metal 
chelating, radical scavenging and neuroprotective properties.84 Very recently, Dutta and co-workers 
developed a multifunctional compound with highly potent dopamine D2/D3 agonist activity, which 
 77 
acts as an iron chelator.88 Hybrid compounds consisting of 6-chlorotacrine and 8-hydroxyquinoline 
scaffolds connected through an oligomethylene linker have been designed as potential anti-AD drug 
candidates.85  
Ghaemmaghami et al. have recently proposed a class of 8-hydroxyquinoline derivatives as antiprion 
compounds (see 21 in Figure 34).86 
 
Figure 34. 8-hydroxyquinoline derivatives 
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6. Parallel synthesis, evaluation, and preliminary 
 structure activity relationship of 2,5-diamino-1,4-
 benzoquinones as a novel class of bivalent anti-prion 
 compounds 
 
Most of the anti-prion molecules that have been identified so far derive from screening approaches. 
Structurally, diverse chemical antiprion compounds covering a broad range of the chemical space 
have been identified. Intriguingly, most of them share a common bivalent structure (Figure 35). 
This is the case of the diphenyl-methane derivatives GN8 (1), the bis-acridine analogues (BiCappa, 
15),1 the natural products curcumin (22),2 bebeerine (23),1,3 and bisepigallocatechin digallate (24),4,5 
2,2’-bisquinolines (8),6 4,5-dianilinophthalimide (25),6 analogues of Congo red (26),7 and 
diketopiperazines (DKP) derivatives (27).8  
 
Figure 35. Design strategy leading to novel BQ derivatives 
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Bivalency, and multivalency in general, is a well-known and efficient strategy widely used by 
medicinal chemists to enhance binding efficacy in molecular recognition processes.9 Multivalent 
chemical probes, featuring multiple copies of an amyloid binding motif connected by a spacer, have 
been developed with the aim to simultaneously bind to several binding sites or several amyloid 
peptides, thus achieving higher potency.9  
Assembling multiple acridine or curcumin moieties to a cyclopeptide scaffold has emerged as a 
promising strategy for the development of inhibitors against fibril formation.10,11 and bivalent 
“molecular tweezers” have been envisaged as the next generation of amyloid ligands.12 
In prion research, by joining two quinacrine moieties through a piperazine spacer, May et al. 
afforded the first bivalent anti-prion ligand BiCappa (15), which was 100 times more potent than 
monomeric 2.1 Building on the bivalent approach, we have designed a library of 14 ligands obtained 
by combining two different BQ cores with seven amino acid methyl esters. The library was 
prepared and tested for prion replication inhibition in ScGT1 cells. Despite the small number of 
synthesized compounds, some of them were active against prion replication. 
Based on these results, we envisaged that bivalent ligands bearing two PRMs connected by a central 
BQ core might possess promising anti-prion activity. Furthermore, thanks to the antioxidant 
properties of the BQ nucleus, bivalent BQ derivatives might act as MTDLs against prion diseases. 
Thus, we decided to design a further combinatorial library of twelve entries, featuring an 
antioxidant BQ nucleus as spacer connecting acridines and quinolines as PRMs. 
In the following, the design, synthesis and biological evaluation of the two compound libraries will 
be reported.  
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6.1.  Development of a library of BQ-amino acids bivalent ligands 
As already discussed, the conformational transition process of PrPC to PrPSc remains enigmatic. 
However, regardless of the initiating event, PrPSc appears to act as a conformational template by 
which PrPC is converted to a new molecule of PrPSc, through PPIs. PPIs are crucial elements in 
mediating diverse cellular physiological and pathological events. They play a pivotal role in the 
pathogenesis of conformational neurodegenerative diseases, as PPIs are involved in fibrillation 
processes.13 Systematic analyses of PPI interfaces reveal a highly heterogeneity in size of the 
contact area, polarity of the interface, protrusion and flatness.14,15 However, the majority of PPIs 
deals with cavity-less proteins, where a complex network of weak interactions takes place. Peptides 
have been proposed to be good PPIs blockers.16 So far, several peptides have been developed with 
the specific aim of blocking PPIs and of reversing the aberrant conformational changes. A short 
synthetic peptide (iPrP13, DAPAAPAGPAVPV)17 designed by Soto on the basis of sequence 
homology with PrPC, acted as a β-sheet breaker, inducing unfolding of β-pleated sheet structure. 
More recently, Gilbert and co-workers18 have reported on a series of small peptides active in the 
high micromolar range in two prion disease models and in an in vitro anti-aggregation 
polymerization assay. However, they are not optimal drug candidates, due to problems with 
bioavailability and enzymatic degradation. To overcome this limitation, one could use libraries 
based on small molecules. However, the widely spaced interactions required for PPI’s blockers are 
difficult to mimic with small molecules. In spite of this challenge, Janda and co-workers have 
recently demonstrated the ability of what they have named “credit card” libraries to disrupt PPIs of 
biological relevance.19 The chemical structures of these libraries are built upon flat, rigid scaffolds, 
decorated with appended groups that span a wide range of size, aromaticity, polarity, and hydrogen-
bonding capability.16,20,21 Their rationale was based on the concept that the “hot spot” regions in 
protein−protein interfaces are rich in aromatic residues. Prompted by the advantages of using small 
molecules as PPI inhibitors as opposed to peptides, here we propose the planar BQ scaffold as a 
privileged motif in modulating PPIs. This is based on (i) Janda’s criteria for credit card libraries;19 
(ii) the finding that a 2,5-bisdiamino-benzoquinone derivative binds to β-amyloid (Aβ), and 
interferes with the native ability of Aβ to self-assemble, by disrupting PPIs.22 As highlighted above, 
due to a resonance effect, a hydrophobic and planar system is generated in 2,5-bisdiamino-
benzoquinones. This should, in principle, perturb PPIs in the fibrillogenesis processes.23 
Therefore, in our search for novel anti-prion compounds, we decided to attach seven amino acids 
methyl esters to two different benzoquinone cores, generating a small combinatorial library of 
fourteen 2,5-bisdiamino-benzoquinones peptidomimetics (28a-g and 29a-g), reported in Figure 36. 
The selected amino acid esters (AlaOMe (a), Nω-Nitro-ArgOMe (b), Nε-BOC-LysOMe (c), 
IleOMe (d), MetOMe (e), PheOMe (f), TrpOMe (g)) act as capping groups, allowing us to enlarge 
the library’s chemical diversity by exploiting differences in size, aromaticity, polarity, and 
 83 
hydrogen-bonding capability. Analysis of natural amino acids involved in PPIs revealed that Trp, 
Phe, Tyr, and Ile are the most important in driving aggregation.14 Consequently, it is highly 
conceivable that the novel derivatives bearing these motifs might compete for binding and, 
therefore, efficiently disrupt the assembly of prion protein. 
 
Figure 36. Chemical structures of 28a-g and 29a-g. 
 
A cell-based screening assay was used to test anti-prion activity across the synthesized library of 
compounds (see Experimental Section, Chapter 10).  
Notably, three hit compounds (28f-g, 29f) of library were active against PrPSc accumulation. For 28f 
a remarkable submicromolar EC50 value (0.87 µM) was found, comparable to that of 2 (0.4 µM). 
The high activity of 28f-g and 29f was not unexpected (see Ref. 24), as it is in line with the well-
known central role of pi-stacking interactions in self-assembly processes in the fields of chemistry 
and biochemistry.25 To better rationalize the obtained results, a systematic procedure for identifying 
key fragments responsible for a given activity was applied.26 In this protocol an algorithm, which 
breaks down a structure into fragments, was used.h Subsequently, all the obtained substructures 
were related to biological activities to identify hot fragments (Figure 37, for method see Appendix 
                                                      
h Fragmenter was used for molecular decomposition to fragments and R-groups, JChem 5.0.0, 2008, ChemAxon 
(http://www.chemaxon.com) 
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A for the methods used). From this preliminary computational study, we have identified that the BQ 
nucleus connected with two phenyl rings by a linker is a good anti-prion motif. In addition, our 
analysis suggests the relevance of the atomic size of the substituents in position 3 and 6 at BQ ring 
(Cl better than Br), with an inverse relation to van der Waals radius (Figure 37). 
 
Figure 37. Substructures identified from the synthesized library. 
 
6.2. Development of a library of BQ-PRM bivalent ligands 
The data coming from the previous investigation have been exploited for the design of a further 
series of anti-prion small molecules.  
We designed a small combinatorial library of MTDLs, whose general structure is depicted in 
Figure 38. We hypothesized that the presence of a PRM, key element for anti-prion activity,18 along 
with a moiety endowed with an alternative mechanism of action against prion diseases might lead to 
discover more effective compounds.27 The ligands feature the antioxidant BQ nucleus as central 
core, with two linkers in position 2 and 5 connecting two PRMs as terminal moieties (see Figure 
38). As linkers, we selected three polyamine chains (53-55, Scheme 1) that would allow exploring 
different lengths and chemical composition for the different molecules. This is of particular 
importance, since linker length has shown by May et al. to be very critical against PrPSc formation 
for the bivalent acridines series.1 As terminal moieties, starting from the consideration that aromatic 
groups provided the best activity in the previous series of BQ compounds,24 we selected three 
aromatic prion recognition motifs, such as 6-chloro-2-methoxyacridine (as in 30-32, Scheme 1), 7-
chloroquinoline (33-35), and 1,2,3,4-tetrahydroacridine (36-38). 
The choice of these as PRM was motivated by our 28 and by others’ results.1,29,30 Moreover it was 
strongly supported by the studies of Cordeiro et al. that experimentally demonstrated that 45 
reduces the aggregation of the ShaPrP peptide into amyloid-like structures31, and by the SPR studies 
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of Go et al. demonstrating that 42 and 43 are strong binders of hPrPC.32,33 As discussed earlier, 
acridines and quinolines can be classified as a privileged structures, with optimal pharmacokinetic 
properties and a high degree of drug-likeness, extremely favorable features when starting a drug 
discovery program.1,29,30 Given that the derivatives of 1,2,3,4-tetrahydroacridin-9-amine (58) are 
active against yeast prion34 and antiprion ScN2a cells,33 36-38 (see Scheme 1), were also designed. 
As a second step, on the basis of the remarkable profile shown by 34, three other derivatives (39-41) 
were designed with the aim of further optimizing activity in the existing series of compounds. In the 
following sections, we present a solution-phase parallel synthesis of the designed library of bivalent 
BQ derivatives (see Scheme 1), which were evaluated for their anti-prion activity in ScGT1 cells, 
together with their capability of inhibiting PrPSc aggregation and of reducing OS. 
 
Figure 38. Rational design of library compounds 30-41. 
 
 
 
6.2.1.  Chemistry  
We synthesized the designed bivalent compounds 30-40 using a solution phase parallel synthesis 
approach. The group of Prof. Bolognesi has previously reported how a di-substitution reaction of 
diamines with 2,5-dimethoxy-1,4-benzoquinone provides easy access to a variety of 2,5-diamino-
1,4-benzoquinones.23,35 Encouraged by the good yields and the straightforward work-up associated 
with this reaction, we followed the following procedure. Eleven N-substituted polyamines (42-52, 
Scheme 1) were loaded with 2,5-dimethoxy-1,4-benzoquinone into different vessels of a carousel 
workstation. After heating at 50 °C for 5 hours, the desired products formed in moderate to good 
yields (38−88%). Monovalent 41 was obtained by Michael reaction starting from naftoquinone and 
amine 46 (40%). The preparation of intermediates 42-52 was easily achieved treating in parallel 
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fashion commercially available polyamines 53-55 with heteroaryl halides 56-60. Compounds 42-52 
were obtained in 25-67% yield by reacting a large excess of the polyamine with the corresponding 
heteroaryl halide (27:1) in phenol and using NaI as a catalyst (Scheme 1). In these conditions we 
were able to obtain selective mono-substitution at the terminal primary amino group of the 
polyamine, obviating the need for protection/deprotection of the other amino functionalities.36 
Furthermore, we overcame the low-yield of common SNAr reactions, and the use of costly reagents 
of Pd-catalyzed amination methodologies.37  
 
Scheme 1. Reagents and conditions: (a) phenol, NaI, 120 °C (1 h), followed by addition of amine, 5 h, 120 
°C; (b) EtOH, 5 h, 60 °C (38-88% yield); (c) EtOH, 80 °C (1 h), followed by addition of amine, 5 h, 50 °C 
(40%). 
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6.2.2. Results and Discussion 
A cell-screening assay was used to test toxicity and anti-prion activity across the library of 
synthesized compounds (see Experimental Section, Chapter 10). In addition, for compounds 15, 
31, 34, 35 and 39, the capability to inhibit prion fibril formation was studied in vitro by using a 
previously reported amyloid seeding assay.38 Prion fibril formation inhibitory activity was evaluated 
by measuring the increase of the lag phase of PrP amyloid formation kinetics. Antioxidant potential 
of the most active BQ derivatives (16, 31, 34, 35 and 39) in ScGT1 cell lines was evaluated by 
using the thiobarbituric acid reactive substances (TBARS) assay and sulforaphan (4-
methylsulfinylbutyl isothiocyanate, SFP) assay (see Experimental Section, Chapter 10). 
Preliminarily, the possible toxicity of the compounds 30-38 was assessed in ScGT1 cells. At 1 µM 
concentration, the toxicity profiles among the library members varied from 1.5% to 114.8% (see 
Table 4). 
Table 4. Cell viability and anti-prion activity on ScGT1 cells of library compounds. 
Compound % of viable cells at 1 µMb % of PrP
Sc inhibition at 
1 µMc 
% of viable 
cells at EC50b 
EC50 (µM)c 
Lag Phase 
(hours)d 
2 98.5 ± 3.9a 103.8 ±6.1a 100.0 ± 4.3 0.4 ± 0.1a   
15 75.6 ± 7.1 102.1 ± 2.7 92.4 ± 6.2a 0.32 ± 0.03 55 ± 7* 
30 18.2 ± 1.2 80.1 ± 6.3 (at 0.2 µM) 
ND 
3.1 ± 0.3 (at 0.2 µM)    
31 65.5 ± 5.6 89.7 ± 5.1 75.2 ± 8.4 0.68 ± 0.05 45 ± 10# 
32 1.5 ± 0.2 65.8 ± 4.6(at 0.2 µM) 
ND 
5.4 ± 0.4 (at 0.2 µM)    
33 114.8 ± 7.9 6.2 ± 0.6    
34 100.4 ± 3.6 85.5 ± 3.9 99.6 ± 2.7 0.73 ± 0.03 53 ± 5# 
35 105.0 ± 7.4 49.1 ± 2.2 91.3 ± 4.2 1.2 ± 0.1 40 ± 10* 
36 108.0 ± 8.4 7.1 ± 0.9    
37 104.4 ± 5.6 3.6 ± 0.4    
38 95.4 ± 7.4 3.4 ± 0.2    
39 78.6 ± 5.2 105.3 ± 5.5 101.5 ± 3.6 0.17 ± 0.01 57 ± 6# 
40 87.2 ± 5.8 4.7 ± 0.3    
41 94.3 ± 3.8 2.9 ± 0.1    
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Treatment with 30 and 32 decreased cell viability to percentages of 18.2% and 1.5%, respectively. 
Because of the toxicity shown, 30 and 32 were studied for their anti-prion activity at a lower 
concentration (0.2 µM), whereas the other library members were assayed at a concentration of 1 
µM. The synthesized compounds 31, 33-35 were found to cover a broad range of activity against 
PrPSc formation, with percentages of inhibition spanning from 3.4% to 89.7% (Table 4). 
Compounds 30-32, bearing an acridine moiety, displayed a general higher toxicity in the cell 
viability assay. 31 turned out to be the most active anti-prion compound, with a submicromolar 
EC50 value (0.68 ± 0.05 µM) and a percentage of viable cells at EC50 of 75.2%. A different toxicity 
profile was observed for quinoline derivatives 33-35, which were not toxic to ScGT1 cells (cell 
viability > 100% at 1 µM concentration). Intriguingly, 34 and 35 showed also remarkable 
submicromolar EC50 values (0.73 ± 0.03 µM, and 1.2 ± 0.1 µM, respectively; Figure 39) 
comparable to that of 15 (0.32 ± 0.03 µM).  
 
Figure 39. Western blot of protease-digested ScGT1 cell lysates depicting the presence or absence of PrPSc 
after treatment with 15, 31, 34, 35, 39 before (up) or after (bottom) PK: Ctrl = control. Survival of ScGT1 
cells treated with 39. 
a Values are the mean of three experiments, standard deviations are given. b ScGT1 cells were cultured in DMEM with 10% FBS, 
plated 25000 cells in each well of 96-well plates. The compounds were dissolved in DMSO (100%) and diluted in PBS 1X before 
adding various concentrations (10 nM - 10 µM) and incubated for 5 days at 37°C, 5% CO2. The results were developed by calcein-
AM fluorescence dye and read by microplate reader. c The effect of library compounds on inhibition of scrapie prion replication. 
ScGT1 cells were cultured in DMEM with 10% FBS, split 1:10 into Petri dishes and incubated for 2 days at 37°C and 5% CO2. 
Then, various compound concentrations (10 nM - 2 µM), being non-toxic for the cells, were added to the plates. After a 5-day 
incubation, proteins of cells were extracted, quantified, digested with proteinase K (PK), and western-blotted. d Prion fibril formation 
inhibitory activity in vitro (Control 45 ± 4 h). Statistical analysis was done by analysis of Student’s t-test (n=4); (*) p e 0.05, (#) p e 
0.01. 
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To note, a series of bisquinolines with a polyamine linker have been already designed and tested in 
ScN2a cell line, but showed a lower activity against prion infection (in the one-digit micromolar 
range).39 This might confirm the design rationale, indicating that the presence of a BQ core is 
critical for activity. The replacement of the 2,6-disubstited acridine ring of 30-32 with the 
unsubstituted 1,2,3,4-tetrahydroacridine, as in 36-38, resulted in a complete loss of activity, 
pointing out to the role for the aromatic substituents in the recognition process. Interestingly, these 
latter compounds did not show toxicity in ScGT1 cells. For all the three series (30-32, 33-35, and 
36-38), data from the cell-screening assay suggest that a linker length of three methylenes is 
important for optimal anti-prion activity. Intriguingly, a similar trend was observed by May et al. in 
their series of analogous bivalent ligands.1 Altogether, these preliminary results suggest that a 
specific length of the linker and the presence of a chlorine substituent on the prion recognition 
motifs might contribute to activity against PrPSc formation. Regarding toxicity, the presence of the 
acridine ring seems to be a major determinant, in line with the reported DNA intercalation 
properties of this heterocycle.1 Conversely, quinoline and 1,2,3,4-tetrahydroacridine moieties do not 
confer cytotoxicity.  
As a second step, based on the remarkable profile shown by 34 (Scheme 1), three other derivatives 
(39-41) were designed with the aim of further optimizing activity in the existing series of 
compounds. Indeed, we decided to synthesize a second set of compounds in which the effect of the 
substituents on the heteroaromatic ring was investigated by synthesizing the 6-chloro-1,2,3,4-
tetrahydroacridine (39) and the 6-methoxyquinoline (40) derivatives. Furthermore, to probe the 
bivalent mechanism of action of 34, its corresponding monomeric derivative 41 was designed. 
From the biological studies (see Experimental Section, Chapter 10), as expected, quinoline 40, 
lacking the chlorine atom, resulted not toxic against ScGT1 cells, while displaying negligible 
activity against prion replication (inhibition of 4.7%, Table 4). These results again point out the 
critical role played by the chlorine substituent of the aromatic ring. This speculation was further 
confirmed by the outstanding activity shown by the 6-chloro-1,2,3,4-tetrahydroacridine 39. In 
contrast to 37, which does not carry the chlorine atom and is devoid of anti-prion activity, 39 
showed a remarkable EC50 value of 0.17 µM, which is the lowest among the present series of BQ 
derivatives, even better than that of BiCappa. Remarkably, 39 showed a concomitant low toxicity 
(101.5% of viable cells at EC50 value, see Table 4).  
In order to study the mechanism of action of the most active compounds (31, 34, 35 and 39) at a 
molecular level, a PrP amyloid fibrillation assay was used. Only 34, 39 and BiCappa (15), at 2 µM, 
exhibited significant PrP amyloid fibril forming inhibitory activity. In fact, they extended the lag 
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phase to a time ≥ to 53 hours, showing a significantly slower kinetics than the control (45 hours, 
Table 4). These results, although preliminary, are in agreement with the starting hypothesis that 
bivalent ligands might interact directly with the recPrP to prevent its conversion to misfolded PrPSc 
isoform. Furthermore, the idea that hydrophobic and planar molecular features are crucial to perturb 
PPIs in the prion fibrillogenesis processes seems confirmed. In addition, a key molecular 
determinant seems to be the presence of a chlorine substituent on the heteroaromatic terminal 
moieties.  
The PrPSc infected cells are under OS, mainly caused by mitochondrial dysfunction.40,41 In light of 
this, antioxidants able to scavenge or neutralize ROS might be beneficial against prion diseases.42 
Indeed, derivatives of 16 has been proposed for prion and other neurodegenerative diseases.43-47 
Thus, we tested the antioxidant potential of the most active BQ derivatives (2, 5, 6 and 10) in 
ScGT1 cell lines, by using the thiobarbituric acid reactive substances (TBARS) assay and the 
antioxidant Trolox as a positive control.43-46 The assay measures lipid hydroperoxides and aldehydes 
expressed as an average percent of thiobarbituric acid reactive substances (TBARS) of treated cells 
versus control untreated cells. As shown in Figure 40, derivatives 31, 34 and 35 displayed low 
antioxidant activity (83-87%) at 1 µM, while 39 behaves similarly to Trolox (69% Vs 71%, 
respectively). As expected, BiCappa (15), which does not carry a BQ scaffold, did not show any 
antioxidant capacity (93%). 
 
Figure 40. Effect of Trolox, 15, 31, 34, 35 and 39 (1 µM) on ScGT1, evaluated by TBARS formation. Values 
are the mean ±	 SD (n = 3). 
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We have previously demonstrated that the antioxidant property of related BQ derivatives,23,35 and 
CoQ (16) itself, concerns mainly their reduced hydroquinone forms. NQO1, an inducible enzyme 
that catalyzes the reduction of quinones to hydroquinones, was shown to be responsible for the 
production of the 16-reduced antioxidant forms, as well as that of BQ derivatives.23,35 Therefore, 
since 31, 34, 35 and 39 share the same BQ nucleus, their antioxidant activity was also evaluated in 
ScGT1, following exposure to t-BuOOH, and in the absence or presence of pre-treatment with 
sulforaphane, an inducer of NQO1. Figure 41 clearly shows that 31, 34, 35 and 39 (at 1 µM) in 
their oxidized form show a basal antioxidant activity, but this activity was increased in cells pre-
treated with sulforaphane, confirming that NQO1 is involved in the activation of BQ derivatives. As 
expected, the antioxidant activity of 15 is not influenced by the overexpression of NQO1. 
 
Figure 41. Antioxidant activity of 15, 31, 34, 35 and 39 in ScGT1 cells against ROS formation induced by t-
BuOOH. Experiments were performed with ScGT1 cells treated or not with 2.5 µM SFP: (*) p ≤ 0.05 with 
respect to t-BuOOH treated samples; (#) p ≤ 0.05 with respect to t-BuOOH + SFP treated samples. 
 
These results confirmed the rationale for the design of bivalent anti-prion ligands. 7-
chloroquinolines (34 and 35) and 6-chloro-1,2,3,4-tetrahydroacridine (39) derivatives showed a 
concomitant encouraging low toxicity (Table 4). Notably, the EC50 value of 39 was even lower than 
that displayed by 15, which is a reference compound for prion diseases. Furthermore, 39 showed the 
largest correlation between the cellular anti-prion activity and the capability to inhibit PrP fibril and 
ROS formation. Although its mechanism of action is not fully disclosed, we assume that the 
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bivalent structure of 39 favours the interaction with prion recognition domains, whereas the spacer 
acts simultaneously as a disrupting element against PPIs and an effective antioxidant moiety. 
Remarkably, the 6-chloro-1,2,3,4-tetrahydroacridine scaffold emerges as an effective and 
completely novel prion recognition motif. In conclusion, the present series of molecules are 
chemical probes that may facilitate the exploration of the molecular mechanism underlying prion 
disease. We envisage that a better understanding of the molecular framework of bivalent ligands 
capable of inhibiting prion aggregation and OS would facilitate the creation of new effective anti-
prion agents. 
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7. Development of hybrid lipoic acid derivatives 
 against prion diseases  
 
In Chapter 6, we reported on a new class of anti-prion compounds obtained by linking the 
antioxidant nucleus of BQ to several heterocyclic scaffolds potentially able to perturb PPIs in prion 
(9-amino-6-chloro-2-methoxyacridine, or 4-amino-7-chloroquinoline or 9-amino-6-chloro-1,2,3,4-
tetrahydroacridine). These compounds displayed a multitarget profile, effectively contrasting both 
prion fibril formation and OS in a cell culture model of prion replication. We hypothesized that the 
presence of a PRM along with a moiety endowed with an alternative mechanism of action against 
prion diseases might lead to discover more effective compounds (Figure 42).1 Building on these 
consideration, we designed another class of potential MTDLs, where as antioxidant fragment we 
selected lipoic acid (17). This choice was motivated by the following reasons: (i) 17 is an 
endogenous antioxidant; (ii) well-tolerated in vivo; (iii) effective against fibril formation; (iv) 
chemically linkable to the amine group of 42-43 and 45-46 by amide bond formation.2 17 has also 
been proposed as a lead structure for designing MTDLs for neurodegeneration.2 More importantly, 
17 was administered together with other antioxidants to a patient affected by prion disesases, 
showing moderate therapeutic effects.3 
 
Figure 42. Rational design of 61-65 compounds  
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Two quinoline- (61-62) and two acridine- (63-64) lipoic acid hybrids differing in the diamino linker 
length were hence designed (Figure 45) and tested. Based on the structure similarity, also 
compound 65 (Lipocrine®; PCT Int Appl. 2006, WO2006080043), developed as a promising lead 
candidate for the treatment of AD, was included in the present investigation.4  
7.1. Chemistry 
We have previously reported how a coupling reaction of diamines with lipoic acid (17) provides 
easy access to a variety of derivatives.4 We decided to synthesize the designed compounds 61-64 
following the reported procedure.4,5 17 was loaded with EDCI, HOBT and NEt3 then the proper N-
substituted diamine (42-43 and 45-46, Scheme 2) was added at 0 °C for 2 hours. After stirring 
overnight at room temperature, the desired product was obtained in good yields (67-96%). The 
preparation of intermediate 42-43 and 45-46 was easily achieved by parallel synth  esis as described 
before (see Scheme 1).  
 
Scheme 2. Reagents and conditions: a) EDCI, HOBt, Et3N, CH2Cl2, 0 °C, 0.5 h; then amine 42-43 
and 45-46, RT, overnight, 67– 96% yields; b) see Reference Rosini et al. 2005 
7.2. Results and Discussion 
As for the previous studies, preliminarily, the possible toxicity of the hybrid compounds 61-65 was 
assessed in ScGT1 cells (see Experimental Section, Chapter 10). At 1 µM concentration, the 
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toxicity profile among 61-65 was low, only acridine 63 caused a decrease in cell viability to 88.0% 
of control. Therefore they were studied for their anti-prion activity at the same concentration (47). 
Quinoline-based hybrids 61 and 62 turned out to have low anti-prion activity (inhibition of 8.7% 
and 13.4% at 1 µM, respectively), while acridines 63 and 64 displayed high activity against prion 
replication (inhibition of 107% and 102%). Tetrahydroacridine 65 showed an intermediate profile 
(68%). Consistent with the percent inhibition data, 63 and 64 showed remarkable EC50 values of 
0.18 µM and 0.15 µM, respectively, which are the lowest among the class of the synthesized 
derivatives and even better than the reference drug 2 (EC50 = 0.4 ± 0.1 µM) (Figure 43 and Table 
5). From the data of Table 5, 64 emerged as the hit compound of the present series. To better 
investigate its multitarget activity, we thought interesting to test the cellular anti-prion activity of its 
starting fragments (17 and 42; Scheme 2). As expected, 42 did inhibit prion replication with a 
submicromolar activity (0.35 µM), and thus it can be truly considered a PRM. Interestingly, lipoic 
acid (17) possessed a promising activity against PrPSc formation (EC50 = 5.3 ± 0.4 µM), together 
with an optimal toxicity profile (no toxic effects up to 100 µM). To our knowledge, this is the first 
time that the proposed anti-prion potential of 17 has been demonstrated in a cellular model. More 
importantly, 64 showed an improved anti-prion activity as much as 35-fold over 17 and 2.3-fold 
over 42. 
 
Table 5. Cell viability and antiprion activity of library compounds on ScGT1 cells. 
Compound % of viable cells at 1 µMb 
% of PrPSc inhibition at 
1 µMc 
% of viable cells 
at EC50b 
EC50 (µM)c 
2 98.5 ± 3.9a 103.8 ± 6.1a 100.0 ± 4.3a 0.4 ± 0.1a 
61 100.7 ± 2.2 8.7 ± 0.5 95.8 ± 3.5 5.6 ± 0.1 
62 101.6 ± 4.3 13.4 ± 0.6 100.8 ± 2.6 3.2 ± 0.2 
63 88.1 ± 2.3 107.1 ± 3.0 101.9 ± 3.3 0.18 ± 0.01 
64 94.3 ± 5.6 102.5 ± 5.8 92.1 ± 5.2 0.15 ± 0.01 
65 95.9 ± 2.1 68.3 ± 2.2 94.8 ± 5.5 0.85 ± 0.05 
17  103.0 ± 1.9 2.6 ± 0.1 95.4 ± 4.2 5.3 ± 0.4 
42 88.0 ± 5.7 98.5 ± 5.4 95.4 ± 3.9 0.35 ± 0.02 
a Values are the mean of three experiments, standard deviations are given. b ScGT1 cells were cultured in DMEM with 10% 
FBS, plated 25000 cells in each well of 96-well plates. The compounds were dissolved in DMSO (100%) and diluted in PBS 
1X before adding various concentrations (10 nM - 10 µM) and incubated for 5 days at 37°C, 5% CO2. The results were 
developed by calcein-AM fluorescence dye and read by microplate reader. c The effect of library compounds on inhibition of 
scrapie prion replication. ScGT1 cells were cultured in DMEM with 10% FBS, split 1:10 into Petri dishes and incubated for 2 
days at 37°C and 5% CO2. Then, various compound concentrations (10 nM - 2 µM), being non-toxic for the cells, were added 
to the plates. After a 5-day incubation, proteins of cells were extracted, quantified, digested with proteinase K (PK), and 
western-blotted.  
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Figure 43. A) Western blot of protease-digested ScGT1 cell lysates depicting the presence or absence of 
prions (PrPSc) after treatment with 64, before (up) or after (bottom) PK. B) Survival of ScGT1 cells treated 
with 64. 
 
To study at a molecular level the mechanism of action of the active compounds and fragments (61-
65, 17, and 42), a PrP amyloid seeding assay was performed. All molecules were capable of 
delaying fibril formation, with lag phase spanning from 52 to 70 hours (control 49 hours, Figure 
44). Intriguingly, their in vitro anti-fibril activity parallels the cellular anti-prion profile. In fact, 63, 
64 and 65, which were the most active in ScGT1 cell line, resulted the most active also in this assay. 
63 and 64 extended the lag phase to a time ≥ 68 hours, showing a significantly slower kinetics than 
the control (Figure 44). The good activity shown by 42, although preliminary, is in agreement with 
the starting hypothesis that such a PRM might interact directly with PrP to prevent its conversion to 
the misfolded PrPSc isoform.	  Furthermore, the low anti-amyloid activity of 17 vs those of hybrids 
61-65 suggests that marked aggregation inhibition may be achieved only when 17 and a suitable 
PRM are combined into the same structure, as in 63 and 64. 
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Figure 44. Prion fibril formation inhibitory activity in vitro for 61-65, 17, and 42 (10 µM). Statistical analysis 
was done by analysis of Student’s t-test (n=4); (*) p ≤ 0.01, (#) p ≤ 0.05; Ctrl = control. 
 
As highlited above, the PrPSc infected cells are under OS, mainly caused by mitochondrial 
dysfunction.6-8 In light of this, antioxidant fragments might be beneficial against prion diseases. 
Indeed, lipoic acid hybrids, such as 65 4, scavenge ROS, and they have been proposed for the 
treatment of other multifactorial neurodegenerative diseases.2,5 Thus, we tested the antioxidant 
potential of the most active lipoyl-derivatives (63-65) in ScGT1 cell line, by using the TBARS 
assay. The assay measures lipid hydroperoxides and aldehydes expressed as an average percent of 
TBARS of treated cells versus control untreated cells. Figure 45 clearly shows that 63 and 64 
displayed antioxidant activity (78-82% of control) at 1 µM, while 65 was even better than Trolox 
(58% vs 71%, respectively).  
  
Figure 45. Effect of compounds 63–65 (1 µM) on ScGT1, evaluated by thiobarbituric acid reactive 
substances (TBARS) formation. Trolox was used as a positive control. Values are means ± SD (n=3). 
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Although a perfect match with cellular data is not evident, these results confirm the design rationale, 
indicating that the concomitant presence of a PRM and an antioxidant fragment is suitable to the 
discovery of anti-prion MTDLs. As an example, 64, owing to the presence of an antioxidant 
fragment, the lipoic acid (17), and a PRM, the acridine motif (42), is able to simultaneously interact 
with at least two of the multiple targets involved in prion pathology. 64 inhibits PrPSc accumulation, 
delays fibril formation and reduces oxidative stress. Altogether, these in vitro results make 64 an 
effective candidate to be investigated in vivo for its multiple biological properties in prion diseases. 
Furthermore, given the promising cellular anti-prion profile of fragment 17, further efforts towards 
the design of novel lipoyl hybrids are warranted. 
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8. Discovery of novel derivatives as lead antiprion 
compounds with enhanced cell line  activity,  good 
microsomal stability and low toxicity 
 
In this Chapter, we discuss the rational design of an additional series of MTDLs (66-69, structure 
not shown) potentially able to inhibit prion replication through multiple mechanisms.* 
 
8.1. Results and Discussion 
A new MTDL (69) showed a remarkable EC50 value of 0.04 µM, which is the lowest among all the 
classes of synthesized derivatives and even better than the reference compound 2 (EC50 = 0.4 µM). 
 
 
 
* The data in this chapter are hidden because they have not been published yet. 
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9. Conclusions and future perspectives  
Prion diseases are transmissible spongiform encephalopathies (TSEs) where the molecular 
mechanism is based on an aberrant misfolding of the cellular form of the prion protein (PrPC). 
Conversion and replication from PrPC to its pathological form (PrPSc) is followed by aggregation 
and ultimately neurodegeneration in the CNS. To date there are no identified therapies against TSEs 
because the development of antiprion drugs and the understanding of their mechanism of action are 
very difficult and challenging tasks. 
In the first part of my thesis, I presented a computational study on ligand binding to PrPC. 
I contributed to the development of a docking procedure able to characterize binding of small ligand 
1 (2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide)) on hPrPC 
binding sites. It has been shown that 1 stabilize hPrPC binding to the globular domain (as shown by 
NMR experiments published by Kuwata et al.1). Our computational approach, called EMD 
(enhanced molecular docking), which combines standard docking methods with molecular 
dynamics and metadynamics-based free energy simulations (Figure 16) has been discussed. EMD 
protocol was able to account for protein flexibility and it provides detailed information about the 
binding process, binding affinity and ligand-target interactions. Applying EMD procedure on hPrPC, 
it has been found a multiple-pose binding pattern for 1 that could not be obtained by applying only 
standard protocols. Three binding poses are identified, in agreement with NMR data. The predicted 
dissociation free energy turned out to be in very good agreement with experimental data.2,3 In our 
view this result emphasizes the validity of our protocol that it could be now used to predict the 
potency of 1 analogues interacting on hPrPC.  
The second and largest part of my thesis was devoted to design and synthesis of novel ligands 
against prion diseases. Starting from a deep study of the processes causing prion disease 
pathogenesis (protein aggregation; oxidative stress; unbalance of metal ions),4 we rationalized our 
approach to new ligands acting on multiple targets. A design strategy in which two distinct 
pharmacophores are combined in the same structure to afford hybrid molecules was applied. I 
synthesized three libraries of compounds obtained by combining PRMs (acridine and quinoline 
fragments)5 with several antioxidants and chelating fragments.  
First library: Compounds 30-40 (Scheme 1), featuring a BQ nucleus as antioxidant spacer 
connecting two PRMs, were designed and evaluated against prion infection. A promising hit proved 
to be 39, with very good antiprion activity, which is the lowest among the class and even better than 
the reference drug 2 (Figure 26). Although its mechanism of action is not fully disclosed, 39 should 
favour the interaction with prion recognition domains, whereas the BQ nucleus should act 
simultaneously as a disrupting element against PPIs6,7 and an effective antioxidant moiety.8-10 
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Second library: Here, as antioxidant fragment the lipoic acid (17, Scheme 2) has been selected 
because it was reported to be moderately effective in a prion infected patient.13 Five lipoic acid 
hybrids have been developed and all showed good antiprion activity. PrP amyloid seeding assay 
demonstrated that 63 and 64 extended the lag phase. Interestingly, 63 and 64, owing to the presence 
of an antioxidant fragment, the lipoic acid (17), and a PRM, the acridine motif (43 and 42, 
respectively), were able to simultaneously interact with at least two (PPIs and OS) of the multiple 
targets involved in prion pathology. This finding reinforces the usefulness of MTDL strategy to 
design new antiprion compounds.11 
Third library: Here, five ligands able to inhibit prion replication through multiple mechanisms have 
been designed. A new hybrid compound has shown a potent antiprion profile (data not shown).  
In summary, I addressed two key issues in antiprion drug discovery:  
i) To study ligand interacting with cavity-less proteins, such PrPC, a computational protocol (EMD) 
able to predict PrPC-1 interactions was presented. EMD protocol combines standard docking 
calculations with free energy simulations.  
ii) To rational design ligands for multifactorial prion disease pathogenesis. For the first time, a 
design strategy in which two distinct pharmacophores are combined in the same structure to afford 
potent MTDL antiprion compounds has been applied.  
These results represent an excellent initial step toward the development of new ligands for the 
treatment of prion diseases.  
Perspectives 
Future work will investigate the pharmacological profile of 34, 64, 69 (see Figure 1) to assess their 
stability and toxicity in vivo. Over recent years, zebrafish assays have emerged as an important tool 
to predict mammalian adverse drug effects.12 In order to further evaluate the pharmacological 
profile of 34, 64, 69, the survival rate of zebrafish upon exposure to each compound will be 
determined in the laboratory of Prof. Edward Málaga-Trillo (Developmental Neurobiology, 
Department of Biology - University of Konstanz, Germany). Then, it would be very important to 
confirm the antiprion activity in an in vivo mouse model. 
The structure of protein-ligand complex provides a detailed insight into the interactions made 
between the protein and ligand. The determination of the structure of the PrPC in complex with an 
antiprion compound is clearly central to structure-based discovery. Further work needs to be 
performed to estimate the binding of lead compounds presented here to mPrPC. We are planning to 
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use NMR spectroscopy, in collaboration with Prof. Janez Plavec (NMR center, National Institute of 
Chemistry, University of Ljubljana, Slovenia), to evaluate the effect of binding of compound 69 to 
mPrPC.  
Computational studies will be combined with the NMR data to study PrPC–69 interactions. This 
work will investigate the binding of 69 to the globular domain of PrPC by using the EMD protocol 
that was established in this thesis. It would be highly interesting to use molecular dynamic 
calculations to design new analogs of 69 with a higher affinity to PrPC, which may eventually show 
an improved activity against PrPSc conversion and replication. 
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10. Experimental section 
 
10.1. Chemistry 
All starting reagents (12, 19, 53-60, 70-73) and 2 and 15 were of the best grade available from Aldrich. 9-
chloro-1,2,3,4-thydroacridine (29) and 6,9-dichloro-1,2,3,4-tetrahydroacridine (30) were synthesized 
according to the procedure reported by Hu et al..1 Direct infusion ESI-MS spectra were recorded on Waters 
ZQ 4000 apparatus. 1H NMR and 13C NMR spectra were recorded either at 200 MHz (1H) and 50.3 MHz 
(13C) or at 400 MHz (1H) and 100 MHz (13C). Chemical shifts are reported in parts per million (ppm) relative 
to tetramethylsilane (TMS), and spin multiplicities are given as s (singlet), br s (broad singlet), d (doublet), t 
(triplet), or m (multiplet). Elemental analysis was used to confirm ≥ 95% sample purity and the elemental 
compositions of the compounds agreed to within ±0.4% of the calculated value. When the elemental analysis 
is not included, crude compounds were used in the next step without further purification. Chromatographic 
separations were performed on silica gel columns by flash (Kieselgel 40, 0.040-0.063 mm; Merck) 
chromatography. Reactions were followed by thin-layer chromatography (TLC) on Merck (0.25 mm) glass-
packed precoated silica gel plates (60 F254), then visualized in an iodine chamber or with an UV lamp. The 
term “dried” refers to the use of anhydrous sodium sulphate. Compounds were named following IUPAC rules 
as applied by Beilstein-Institute AutoNom (version 2.1), a PC integrated software package for systematic 
names in organic chemistry. 
General Procedure a for the Synthesis of Library Members 42-52 
In distinct reactors, a mixture of the appropriate hetheroaryl halides 56-60 (1 eq) and phenol (10 eq) were 
prepared and the catalyst NaI (0.3 eq) was added to each reactor. The resulting mixtures were carefully heated 
at 120 °C for 1 hour under N2 atmosphere. Then the appropriate amine 53-55 (27 eq) were added to each 
reactor and the resulting solutions were heated for further 5 hours, cooled to room temperature and treated as 
follows. Each mixture was diluted with EtOAc and shaken with 10% KOH solution. The aqueous layer was 
extracted with EtOAc, dried over anhydrous Na2SO4, evaporated. Purification of each crude product by flash 
column chromatography using (Dichloromethane/Methanol/ Ammonia solution) yielded the corresponding 
final amines 42-52. 
General Procedure b for the Synthesis of 2,5-diamino-1,4-benzoquinone Library Members 30-40 
In distinct reactors, 2,5-dimethoxybenzoquinone (1 eq) was suspended in EtOH (15 mL) and heated to 80 
°C until the solid was completely dissolved. After cooling to 50 °C, the appropriate amines 42-42 (2 eq) were 
added each reaction mixture that became progressively clear and red. Each mixture was heated at 50 °C for 5 
h and, after cooling, precipitates formed, which were collected by filtration. The solid was dissolved in 
diethylether (7-10 mL) and trifluoroacetic acid (0.2 mL) was added to the solutions to obtain the 
corresponding trifluoroacetate salts. 
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2,5-bis[2-(6-chloro-2-methoxyacridin-9-ylamino)ethylamino]cyclohexa-2,5-diene-1,4-dione 
bis(trifluoroacetate) (30) 
Following general procedure (b), it was synthesized in 45% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 42 (90.54 mg, 300 µmol). 1H-NMR (DMSO, 200 MHz): δ 3.59-3.61 (m, 4H), 3.91 (s, 
6H), 4.27 (m, 4H), 5.38 (s, 2H), 6.98 (s, 2H), 7.11 (s, 2H), 7.23 (s, 2H), 7.47 (d, J = 9.2 Hz , 2H), 7.67 (d, J = 
9.2 Hz , 2H), 8.48 (d, J = 9.6 Hz , 2H). 13C-NMR (DMSO, 50.3 MHz) δ 25.63, 43.46, 48.62, 52.77, 56.75, 
77.71, 124.43, 151.30, 162.64, 171.50, 183.31, 189.23 Anal. (C38H32Cl2N6O4 2CF3COOH 4H2O) C, H, N: 
calcd, 50.06; 4.20, 8.34; found, 49.98, 3.80, 8.46. ESI-MS m/z: 707 [M + H+ 35Cl], 709 [M + H+ 37Cl]. 
 
2,5-bis[3-(6-chloro-2-methoxyacridin-9-ylamino)propylamino]cyclohexa-2,5-diene-1,4-dione 
bis(trifluoroacetate) (31) 
Following general procedure (b), it was synthesized in 81% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 43 (94.45 mg, 300 µmol). 1H-NMR (CD3OD, 200 MHz): δ 2.13 (m, 4H), 3.22 (br s, 4H), 
3.93 (s, 6H), 4.13 (br s, 4H), 5.15 (s, 2H), 7.42-7.82 (m, 10H), 8.42 (d, 2H). 13C NMR (DMSO, 50.3 MHz) δ 
27.47, 46.76, 56.10, 67.11, 92.22, 110.00, 114.15, 117.36, 120.64, 123.03, 127.04, 138.85, 140.18, 150.86, 
155.88, 156.17, 177.23. Anal. (C40H36Cl2N6O4 2CF3COOH 2H2O) C, H, N: calcd, 52.86; 4.23, 8.41; found, 
52.73, 3.94, 8.41. ESI-MS m/z: 735 [M + H+ 35Cl], 737 [M + H+ 37Cl], 757 [M + Na+ 35Cl], 759 [M + Na+ 37Cl]. 
 
2,5-bis{3-[3-(6-chloro-2-methoxyacridin-9-ylamino)propylamino]propylamino}cyclohexa-2,5-diene-
1,4-dione tetrakis(trifluoroacetate) (32) 
Following general procedure (b), it was synthesized in 38% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 44 (111.89 mg, 300 µmol). 1H-NMR (DMSO, 200 MHz): δ 1.81-1.95 (m, 12H), 2.73-2.83 
(m, 8H), 3.25-3.28 (m, 4H), 3.92 (s, 6H), 5.30 (s, 2H), 7.22 (m, 2H), 7.33-7.37 (m, 4H), 7.99-8.11 (m, 6H). 
13C NMR (DMSO, 50.3 MHz) δ 24.66, 26.24, 39.07, 45.50, 46.07, 55.55, 92.62, 117.48, 120.40, 124.11, 
127.83, 140.89, 151.94, 157.21, 171.89. Anal. (C46H50Cl2N8O2 4CF3COOH) C, H, N: calcd, 53.88; 5.34, 8.99; 
found, 53.32, 5.94, 8.41. ESI-MS m/z: 849 [M + H+ 35Cl], 852 [M + H+ 37Cl]. 
 
2,5-bis[2-(7-chloroquinolin-4-ylamino)ethylamino]cyclohexa-2,5-diene-1,4-dione bis(trifluoroacetate) 
(33) 
Following general procedure (b), it was synthesized in 60% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 45 (66.51 mg, 300 µmol). 1H-NMR (CD3OD, 200 MHz): δ 3.62 (t, J = 5.4 Hz, 4H), 3.83 
(t, J = 5.4 Hz, 4H), 5.36 (s, 2H), 6.96 (d, J = 7 Hz, 2H), 7.67-7.73 (m, 2H), 7.88 (s, 2H), 8.28 (d, J = 9.2 Hz, 
2H), 8.43 (d, J = 7 Hz, 2H). 13C NMR (CD3OD, 50.3 MHz) δ 39.74, 41.17, 67.88, 91.95, 97.95, 117.17, 
118.54, 123.91, 126.94, 139.20, 142.17, 151.34, 156.09, 177.78. Anal. (C28H24Cl2N6O2 2CF3COOH H2O) C, 
H, N: calcd, 48.64, 3.76, 10.59; found, 48.44, 3.56, 10.59. ESI-MS m/z: 547 [M + H+ 35Cl], 549 [M + H+ 37Cl], 
569 [M + Na+ 35Cl], 571 [M + Na+ 37Cl]. 
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2,5-bis[3-(7-chloroquinolin-4-ylamino)propylamino]cyclohexa-2,5-diene-1,4-dione 
bis(trifluoroacetate) (34) 
Following general procedure (b), it was synthesized in 60% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 46 (70.72 mg, 300 µmol). 1H-NMR (CD3OD, 400 MHz): δ 2.12 (q, J = 6.8 Hz, 4H), 3.40 
(t, J = 6.8Hz, 4H), 3.70 (t, J = 6.8Hz, 4H), 5.28 (s, 2H), 6.91 (d, J = 6.8Hz, 2H), 7.69 (d, J = 9.2Hz, 2H), 7.87 
(s, 2H), 8.35 (d, J = 9.2Hz, 2H), 8.41 (d, J = 7.2Hz, 2H). 13C NMR (CD3OD, 100.5 MHz) δ 21.25, 27.42, 
41.01, 42.55, 99.79, 117.03, 118.11, 120.33, 125.95, 128.77, 140.07, 141.05, 143.88, 153.23, 157.68, 179.41. 
Anal. (C30H28Cl2N6O2 2CF3COOH 2H2O) C, H, N: calcd, 48.64; 4.08, 10.01; found, 48.89, 3.69, 10.01. ESI-
MS m/z: 575 [M + H+ 35Cl], 577 [M + H+ 37Cl], 597 [M + Na+ 35Cl] , 599 [M + Na+ 37Cl]. 
 
2,5-bis{3-[3-(7-chloroquinolin-4-ylamino)propylamino]propylamino}cyclohexa-2,5-diene-1,4-dione 
tetrakis(trifluoroacetate) (35) 
Following general procedure (b), it was synthesized in 51% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 47 (87.84 mg, 300 µmol). 1H-NMR (CD3OD, 400 MHz): δ 2.03 (t, J = 7.2 Hz,4H), 2.20 
(t, J = 7.6 Hz, 4H), 3.10 (t, J = 7.6 Hz, 4H), 3.21 (t, J = 7.6 Hz, 4H), 3.30 (m, 4H), 3.71 (t, J = 6.8 Hz, 4H), 
5.12 (br s, 2H), 6.90 (d, J = 7.6 Hz, 2H), 7.65 (d, J = 7.6 Hz, 2H), 7.87 (s, 2H), 8.35 (d, 2H), 8.41 (d, J = 8 Hz, 
2H). 13C NMR (CD3OD, 100.5 MHz) δ 17.18, 24.68, 39.13, 40.56, 45.32, 45.51, 57.15, 98.67, 115.86, 
119.24, 124.90, 127.58, 138.92, 139.87, 142.88, 151.92, 156.51, 178.44. Anal. (C36H42Cl2N8O2 4CF3COOH 
H2O) C, H, N: calcd, 45.41; 4.16, 9.63; found, 45.40, 3.66, 9.94. ESI-MS m/z: 689 [M + H+ 35Cl], 691 [M + 
H+ 37Cl]. 
 
2,5-bis[3-(1,2,3,4-tetrahydroacridin-9-ylamino)ethylamino]cyclohexa-2,5-diene-1,4-dione 
bis(trifluoroacetate) (36) 
Following general procedure (b), it was synthesized in 45% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 48 (72.40 mg, 300 µmol). 1H-NMR (CD3OD, 400 MHz): δ 1.91-1.95 (br s, 8H), 2.69 (s, 
4H), 2.99 (s, 4H), 3.57 (m, 4H), 4.20 (m, 4H), 5.12 (s, 2H), 7.58 (t, J = 8.2 Hz, 2H), 7.70-7.83 (m, 4H), 8.21 
(d, J = 8.2 Hz, 2H). ). 13C NMR (CD3OD, 50.3 MHz) δ 19.31, 20.98, 22.71, 23.47, 27.41, 29.42, 65.50, 93.87, 
115.54, 118.26, 123.96, 124.93, 132.25, 144.83, 150.90, 164.33, 182.95. Anal. (C36H38N6O2 2CF3COOH 
H2O) C, H, N: calcd, 57.69; 5.08, 10.09; found, 57.03, 4.93, 9.75. ESI-MS m/z: 587 [M + H+]. 
 
2,5-bis[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propylamino]cyclohexa-2,5-diene-1,4-dione 
bis(trifluoroacetate) (37) 
Following general procedure (b), it was synthesized in 55% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 49 (76.61 mg, 300 µmol). 1H-NMR (CD3OD, 400 MHz): δ 1.96 (br s, 8H), 2.16 (m, 4H), 
2.69 (br s, 4H), 2.99 (br s, 4H), 3.36 (m, 4H), 4.06 (m, 4H), 5.09 (s, 2H), 7.55 (m, 2H), 7.72 (m, 2H), 7.82 (m, 
2H), 8.33 (d, 2H). 13C NMR (CD3OD, 100.5 MHz) δ 21.74, 22.92, 24.95, 29.30, 29.76, 40.71, 46.70, 93.25, 
111.33, 113.14, 117.85, 120.06, 126.38, 134.07, 139.74, 151.87, 153.01, 158.10, 178.97. Anal. (C38H42N6O2 
2CF3COOH H2O) C, H, N: calcd, 58.60; 5.39, 9.76; found, 57.92, 4.89, 8.95. ESI-MS m/z: 615 [M + H+]. 
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2,5-bis{3-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propylamino]propylamino}cyclohexa-2,5-diene-1,4-
dione tetrakis(trifluoroacetate) (38) 
Following general procedure (b), it was synthesized in 88% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 50 (93.74 mg, 300 µmol). 1H-NMR (CD3OD, 200 MHz): δ 1.15-1.25 (m, 4H), 1.97 (br s, 
12H), 2.17-2.28 (m, 4H), 2.73 (s, 4H), 3.05-3.33 (m, 12H), 4.08 (m, 4H), 5.27 (s, 2H), 7.55-7.58 (m, 2H), 
7.75-7.91 (m, 4H), 8.38 (d, 2H). 13C NMR (CD3OD, 50.3 MHz) δ 13.52, 19.83, 21.04, 23.13, 24.02, 26.37, 
27.46, 38.47, 64.97, 77.56, 91.90, 111.54, 115.40, 118.37, 124.26, 124.75, 132.19, 137.82, 150.34, 151.24, 
156.02, 177.69. Anal. (C44H56N8O2 4CF3COOH H2O) C, H, N: calcd, 51.71, 5.09, 9.11 found, 51.91, 5.19, 
9.31. ESI-MS m/z: 730 [M + H+].  
 
2,5-bis[3-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)propylamino]cyclohexa-2,5-diene-1,4-dione 
tetrakis(trifluoroacetate) (39) 
Following general procedure (b), it was synthesized in 87% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 22 (86.94 mg, 300 µmol). 1H-NMR (CD3OD, 400 MHz): δ 1.90-1.92 (m, 8H), 2.15 (m, 
4H), 2.62 (m, 4H), 2.93 (s, 4H), 3.30 (m, 4H), 3.98 (m, 4H), 5.03 (s, 2H), 7.55 (d, J = 9.6 Hz, 2H), 7.63 (s, 
2H), 8.23 (d, J = 9.6 Hz, 2H). 13C NMR (CD3OD, 100 MHz) δ 20.72, 21.73, 24.21, 28.48, 38.97, 45.49, 
57.09, 57.12, 105.98, 105.99, 112.53, 125.37, 127.90, 151.47, 159.65, 177.65, 181.88. Anal. (C38H40Cl2N6O2 
4CF3COOH H2O) C, H, N: calcd, 54.26, 4.77, 9.04 found, 54.30, 4.81, 9.08. ESI-MS m/z: 683 [M + H+ 
35Cl35Cl], 685 [M + H+ 37Cl35Cl] 687 [M + H+ 37Cl 37Cl]. 
 
2,5-bis[3-(6-methoxyquinolin-4-ylamino)propylamino]cyclohexa-2,5-diene-1,4-dione 
bis(trifluoroacetate) (40) 
Following general procedure (b), it was synthesized in 88% yield from 2,5-dimethoxybenzoquinone (25.22 
mg; 150 µmol) and 52 (69.39 mg, 300 µmol). 1H-NMR (CD3OD, 400 MHz): δ 2.12 (q, J = 6.8 Hz, 4H), 3.37 
(t, J = 6.8Hz, 4H), 3.65 (t, J = 6.8Hz, 4H), 3.96 (s, 6H), 5.23 (s, 2H), 7.13 (d, J = 7.2Hz, 2H), 7.53 (d, J = 
9.2Hz, 2H), 7.66 (s, 2H), 7.74 (d, J = 9.2Hz, 2H), 8.27 (d, J = 7.2Hz, 2H). 13C NMR (CD3OD, 100.5 MHz) δ 
23.44, 26.00, 39.66, 40.96, 55.24, 92.02, 97.42, 101.35, 121.30, 124.97, 130.27, 132.86, 139.78, 151.83, 
155.27, 158.72, 177.91. Anal. (C32H34N6O4 2CF3COOH H2O) C, H, N: calcd, 53.20; 4.71, 10.34; found, 
53.23; 4.74, 10.39. ESI-MS m/z: 567 [M + H]. 
 
2-[3-(7-chloroquinolin-4-ylamino)propylamino]naphthalene-1,4-dione (41) 
A suspension of naphthalene-1,4-dione (100.6 mg; 0.636 mmol) in EtOH (15 mL) was stirred and heated to 
80 °C until the solid was completely dissolved (1h). After cooling to 50 °C, amine 46 (150 mg, 0.636 mmol) 
was added and the resulting mixture was stirred for 5 hours. Removal of the solvent gave a residue that was 
purified by gravity chromatography (CH2Cl2:MeOH:NH4OH, 9:1:0.05) to afford 41 as orange solid (100 mg, 
0.256 mmol, 40%). 1H-NMR (CDCl3, 400 MHz): δ 2.17 (q, 2H), 3.50 (q, 4H), 5.14 (bs, 1H),5.74 (s, 1H), 6.00 
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(brs, 1H), 6.45 (d, J = 5.2Hz, 1H), 7.37 (dd, J = 9.2Hz, J = 2.0Hz, 1H), 7.63 (t, J = 7.6Hz, 1H), 7.68 (d, J = 
8.8 Hz, 1H), 7.75 (t, J = 7.6Hz, J = 1.6Hz, 1H), 7.97 (d, J = 2Hz, 1H), 8.04 (d, J = 6.8 Hz, 1H), 8.10 (d, J = 
7.6 Hz, 1H), 8.56 (d, J = 5.2 Hz, 1H),. 13C NMR (CD3OD, 100.5 MHz) δ 27.40, 40.30, 40.91, 99.22, 101.25, 
117.15, 120.76, 125.64, 126.22, 126.34, 132.15, 133.42, 134.89, 151.98, 182.96. MS m/z: 392 [M + H+ 35Cl], 
394 [M + H+ 37Cl], 414 [M + Na+ 35Cl], 416 [M + Na+ 37Cl]. 
 
N1-(6-chloro-2-methoxyacridin-9-yl)ethane-1,2-diamine (42) 
Following general procedure (a), it was synthesized from 56 (300 mg, 1.08 mmol) and 53 (1.9 mL, 29 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 9:1:0.1) to 
yield 42 (110 mg, 38%). 1H-NMR (CDCl3, 200 MHz): δ 3.71 (m, 2H), 3.97 (m, 2H), 4.03 (s, 3H), 7.15 (d, J = 
9.4 Hz , 1H), 7.36 (s, 1H), 7.41 (s, 1H), 7.92-8.06 (m, 3H) ESI-MS m/z: 302 [M + H+ 35Cl], 304 [M + H+ 37Cl]. 
 
N1-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-diamine (43) 
Following general procedure (a), it was synthesized from 56 (300 mg, 1.08 mmol) and 54 (2.4 mL, 29 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 9:1:0.1) to 
yield 43 (110 mg, 33%). 1H-NMR (CDCl3, 200 MHz): δ 1.77 (quintet, 2H), 3.00 (t, J = 6 Hz, 2H), 3.83 (s, 
3H), 3.86 (t, J = 6 Hz, 2H), 7.08-7.14 (m, 2H), 7.19 (s, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.93 (s, 1H), 8.01 (d, J = 
9.2 Hz, 1H). ESI-MS m/z: 316 [M + H+ 35Cl] 
 
N1-(3-aminopropyl)-N3-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-diamine (44) 
Following general procedure (a), it was synthesized from 56 (300 mg, 1.08 mmol) and 55 (4,1 mL, 29 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 8:2:0.2) to 
yield 44 (150 mg, 37%). 1H-NMR (CDCl3, 200 MHz): δ 1.61-1.68 (m, 4H), 2.62-2.84 (m, 6H), 3.62-3.80 (m, 
2H), 3.83 (s, 3H), 7.04 (m, 1H), 7.24 (m, 2H), 7.79-7.93 (m, 3H). ESI-MS m/z: 373 [M + H+ 35Cl], 375 [M + 
H+ 37Cl]. 
 
N1-(7-chloroquinolin-4-yl) ethane-1,2-diamine (45)  
Following general procedure (a), it was synthesized from 57 (300,0 mg, 1.51 mmol) and 53 (2.7 mL, 41 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 9:1:0.1) to 
yield 45 (223 mg, 67%). 1H-NMR (CDCl3, 200 MHz): δ 3.15 (t, 2H, J = 28 Hz), 3.45 (t, 2H J = 26 Hz), 6.44 
(d, 1H, J = 25 Hz), 7.42-7.36 (m, 1H), 7.52 (d, 1H, J = 25 Hz), 7.98 (s, 1H), 8.57 (d, 1H, J = 27 Hz). ESI-MS 
m/z: 222 [M + H+ 35Cl] 
 
N1-(7-chloroquinolin-4-yl)propane-1,3-diamine (46) 
Following general procedure (a), it was synthesized from 57 (300,0 mg, 1.51 mmol) and 54 (3,4 mL, 41 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 9:1:0.1) to 
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yield 46 (223 mg, 67%). 1H-NMR (CDCl3, 200 MHz): δ 2.97 (t, J = 6.2 Hz, 2H), 3.41 (t, J = 6.2 Hz, 4H), 
6.33 (d, J = 5.2 Hz, 1H), 7.33 (d, J = 9 Hz, 1H), 7.75 (d, J = 9 Hz, 1H), 7.90 (s, 1H), 8.42 (d, J = 5.2 Hz, 1H). 
ESI-MS m/z: 236 [M + H+ 35Cl] 
 
N1-(3-aminopropyl)-N3-(7-chloroquinolin-4-yl)propane-1,3-diamine (47) 
Following general procedure (a), it was synthesized from 57 (300,0 mg, 1.51 mmol) and 55 (5,7 mL, 41 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 8:2:0.2) to 
yield 47 (150 mg, 35%). 1H-NMR (CDCl3, 200 MHz): δ 1.60 (m, 2H), 1.76-1.81 (m, 2H), 2.55-2.75 (m, 6H), 
3.20-3.25 (m, 2H), 6.20 (d, J = 7.2 Hz, 1H), 7.17 (d, J = 8.8 Hz, 1H) , 7.64 (d, J = 8.8 Hz, 1H) , 7.81 (s, 1H) , 
8.33 (d, J = 7.2 Hz, 1H). ESI-MS m/z: 293 [M + H+ 35Cl], 295 [M + H+ 37Cl]. 
 
N1-(1,2,3,4-tetrahydroacridin-9-yl) ethane-1,2-diamine (48) 
Following general procedure (a), it was synthesized from 58 (300,0 mg, 1.51 mmol) and 53 (2.7 mL, 41 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 9:1:0.1) to 
yield 48 (30 mg, 25%). 1H-NMR (CDCl3, 200 MHz): δ 1.92-1.95 (br s, 4H), 2.76 (s, 2H), 3.01 (m, J = 6 Hz, 
4H), 3.16 (t, J = 6 Hz, 2H), 7.34 (t, J = 8.4 Hz,1H), 7.59 (t, J = 8.4 Hz,1H), 8.04 (t, J = 8.4 Hz,2H). ESI-MS 
m/z: 242 [M + H+] 
 
N1-(1,2,3,4-tetrahydroacridin-9-yl)propane-1,3-diamine (49) 
Following general procedure (a), it was synthesized from 58 (300,0 mg, 1.38 mmol) and 54 (3,1 mL, 37 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 9:1:0.1) to 
yield 49 (110 mg, 32%). 1H-NMR (CDCl3, 200 MHz): δ1.77-1.91 (m, 6H), 2.88 (m, 2H), 3.00-3.05 (m, 4H), 
3.57-361 (m,2H) 7.32 (t, 1H, J = 33 Hz), 7.53 (t, 1H, J = 33 Hz), 7.93 (m, 2H ). ESI-MS m/z: 256 [M + H+] 
 
N1-(3-aminopropyl)-N3-(1,2,3,4-tetrahydroacridin-9-yl)propane-1,3-diamine (50) 
Following general procedure (a), it was synthesized from 58 (300,0 mg, 1.38 mmol) and 55 (5,2 mL, 37 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 8:2:0.2) to 
yield 50 (150 mg, 44%). 1H-NMR (CDCl3, 200 MHz): δ 1.49-1.78 (m, 8H), 2.52-2.67 (m, 8H), 2.94 (s, 2H), 
3.48-3.51 (br s, 2H), 7.19 (t, J = 7.2 Hz, 1H), 7.41 (t, J = 7.2 Hz, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.90 (d, J = 
8.6 Hz, 1H). ESI-MS m/z: 313 [M + H+]. 
 
N1-(6-methoxyquinolin-4-yl)propane-1,3-diamine (52) 
Following general procedure (a), it was synthesized from 60 (267,2 mg, 1.38 mmol) and 54 (3,1 mL, 37 
mmol). The crude residue was purified by flash column chromatography (CH2Cl2/CH3OH/NH4OH, 8:2:0.2) to 
yield 52 (223 mg, 70%). 1H-NMR (CDCl3, 200 MHz): δ 1.94 (q, J = 12 Hz, 2H), 3.08 (t, J = 12 Hz, 2H), 3.46 
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(brs, 2H), 6.37 (d, J = 10 Hz, 1H), 7.08 (s, 1H), 7.30 (d, J = 17 Hz, 1H), 7.92 (d, J = 18 Hz, 1H), 8.45 (d, J = 
10 Hz, 1H). ESI-MS m/z: 232 [M + H]. 
 
N-[3-(7-chloroquinolin-4-ylamino)propyl]-5-(1,2-dithiolan-3-yl)pentanamide (61).  
Following general procedure, it was synthesized in 78% yield from N1-(7-chloroquinolin-4-yl)propane-1,3-
diamine (46, 30.0 mg) and 12 (17.5 mg). 1H NMR (CDCl3, 400 MHz) δ 1.35-1.40 (m, 2H), 1.54-1.77 (m, 
5H), 2.20-2.32 (m, 5H), 3.01-3.08 (m, 2H), 3.33-3.39 (m, 3H), 3.69-3.73 (m, 2H), 6.25 (d, J = 5.6 Hz, 1H), 
6.62 (brs, D2O-exchangeable, 1H), 6.82 (brs, D2O-exchangeable, 1H), 7.37 (dd, J = 9.2, J = 2 Hz, 1H), 7.80 
(d, J = 9.2 Hz, 1H), 7.89 (d, J = 2 Hz, 1H), 8.45 (d, J = 5.2 Hz, 1H). 13C NMR (CDCl3, 100.5 MHz) δ 25.53, 
28.32, 28.91, 34.56, 36.20, 36.54, 38.51, 38.97, 40.30, 56.44, 98.33, 117.50, 122.18, 125.53, 127.86, 135.25, 
148.67, 150.24, 151.25, 174.39. Anal. (C20H26ClN3OS2) C, H, N: calcd, 56.65, 6.18, 9.91 found, 56.75, 6.28, 
9.95. MS (ESI+) m/z 424 [M + H+ 35Cl], z 426 [M + H+ 37Cl], 446 [M + H+ 23Na 35Cl], 448 [M + H+ 23Na 37Cl]. 
 
N-[2-(7-chloroquinolin-4-ylamino)ethyl]-5-(1,2-dithiolan-3-yl)pentanamide (62) 
Following the general procedure, it was synthesized in 96% yield from N1-(7-chloroquinolin-4-yl)ethane-
1,2-diamine (45, 53.7 mg) and 12 (33.0 mg). 1H NMR (CDCl3, 400 MHz) δ 1.35-1.42 (m, 2H), 1.54-1.78 (m, 
5H), 2.20-2.34 (m, 3H), 2.99-3.11 (m, 2H), 3.33-3.39 (m, 3H), 3.69-3.75 (m, 2H), 6.25 (d, J = 5.6 Hz, 1H), 
6.62 (brs, D2O-exchangeable, 1H), 6.82 (brs, D2O-exchangeable, 1H), 7.37 (dd, J = 9.2, J = 2, 1H), 7.80 (d, J 
= 8.8 Hz, 1H), 7.89 (s, , J = 2 Hz , 1H), 8.45 (d, J = 5.2 Hz, 1H). 13C NMR (CDCl3, 100.5 MHz) δ 25.37, 
28.68, 34.47, 36.23, 38.41, 38.69, 40.11, 46.06, 56.28, 98.10, 117.19, 122.15, 125.47, 128.03, 134.98, 148.77, 
150.25, 151.66, 176.01. Anal. (C19H24ClN3OS2) C, H, N: calcd, 55.66, 5.90, 10.25 found, 55.49, 5.79, 10.20. 
MS (ESI+) m/z 410 [M + H+ 35Cl], z 412 [M + H+ 37Cl], 432 [M + H+ 23Na 35Cl], 434 [M + H+ 23Na 37Cl].  
 
N-[3-(6-chloro-2-methoxyacridin-9-ylamino)propyl]-5-(1,2-dithiolan-3-yl)pentanamide (63)  
Following the general procedure, it was synthesized in 74% yield from N1-(6-chloro-2-methoxyacridin-9-
yl)propane-1,3-diamine (43, 33.9 mg,) and 12 (31.7 mg). 1H NMR (CDCl3, 400 MHz) δ 1.41-1.54 (m, 2H), 
1.62-1.77 (m, 4H), 1.83-1.91 (m, 1H), 1.94-2.00 (m, 2H), 2.31-2.35 (m, 2H), 2.38-2.42 (m, 1H), 3.05-3.17 (m, 
2H), 3.49-3.57 (m, 3H), 3.86 (t, J = 6.0 Hz, 2H), 4.00 (s, 3H), 6.78 (s, D2O-exchangeable, 1H), 7.20 (dd, J = 
8.8 Hz, J = 2.0 Hz, 1H), 7.35 (dd, J = 9.6 Hz, J = 2.2 Hz, 1H), 7.63 (d, J = 2.8 Hz, 1H), 7.98 (d, J = 9.6 Hz, 
1H), 8.03 (d, J = 2 Hz, 1H), 8.12 (d, J = 9.2 Hz, 1H). 13C NMR (CDCl3, 100.5 MHz) δ 25.44, 28.87, 30.98, 
34.57, 36.18, 36.31, 38.44, 40.22, 45.49, 55.95, 56.41, 100.58, 113.24, 116.58, 124.00, 125.61, 125.76, 
126.90, 128.19, 129.00, 136.86, 144.95, 152.51, 156.28, 174.54 Anal. (C25H30ClN3O2S2) C, H, N: calcd, 
59.56, 6.00, 8.34 found, 59.57, 6.09, 8.34. MS (ESI+) m/z 504 [M + H+ 35Cl], z 506 [M + H+ 37Cl], 526 [M + 
H+ 23Na 35Cl], 528 [M + H+ 23Na 37Cl].  
 
 
 111 
N-[2-(6-chloro-2-methoxyacridin-9-ylamino)ethyl]-5-(1,2-dithiolan-3-yl)pentanamide (64)  
Following the general procedure, it was synthesized in 67% yield from N1-(6-chloro-2-methoxyacridin-9-
yl)ethane-1,2-diamine (42, 33.0 mg,) and 12 (27.9 mg). IR (KBr): 3224, 3060, 2927, 2762, 1629, 1561, 1439, 
1398, 1253, 1172, 1029, 871 cm-1. 1H NMR (CDCl3, 400 MHz) δ 1.37-1.41 (m, 2H), 1.57-1.69 (m, 4H), 1.79-
1.84 (m, 1H), 2.29-2.32 (m, 2H), 2.34-2.40 (m, 1H), 3.04-3.12 (m, 2H), 3.41-3.44 (m, 1H), 3.74-3.77 (m, 2H), 
4.04 (brs, 5H), 7.16 (m, 1H), 7.38 (dd, J = 9.6 Hz, J = 2.2 Hz, 1H), 7.42 (d, J = 2.4 Hz, 1H), 7.98-8.03 (m, 
2H), 8.10 (d, J = 9.2 Hz, 1H). 13C NMR (CDCl3, 100.5 MHz) δ 25.19, 28.73, 34.49, 36.22, 38.47, 40.20, 
40.23, 52.61, 55.86, 56.29, 99.60, 123.45, 124.99, 125.40, 156.09, 175.55 Anal. (C24H38ClN3O2S2) C, H, N: 
calcd, 58.82, 5.76, 8.57 found, 58.57, 5.49, 8.57. MS (ESI+) m/z 490 [M + H+ 35Cl], 492 [M + H+ 37Cl], 512 
[M + H+ 23Na 35Cl].  
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10.2. Biology 
 
Cell culture.  
ScGT1 cells were seeded in 10-cm plates containing 10 mL of Dulbecco’s modified Eagle’s medium 
(DMEM) culture media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. 
The cells were grown at 37°C in 5% CO2 to 95% confluence for 1 week before splitting at 1:10 for further 
cultivation. 
Drug treatment.  
Synthesized compounds were dissolved in 100% dimethyl sulfoxide (DMSO) to a final concentration of 10 
mM. This solution was then further diluted into the final stock solution of 1 mM with 10% (v/v) DMSO/PBS. 
The final concentration of DMSO in the cell medium was never above 0.1%. The media were refreshed and 
the compounds were added to the cultures 2 days after splitting of the cells and incubated for 5 days. Each 
experiment was performed using triplicate cultures. 
Cell viability.  
ScGT1 cells were maintained in DMEM, and supplemented with 10% FBS. After 1 day of incubation, 
media were aspirated from a confluent 10-cm plate of cells, and cells were detached by addition of 1 mL of 
1X trypsin-EDTA solution. Media were added, and cell density determined by cell counting using a 
haemacytometer. The cell density was adjusted to 2.5 × 105 cells/mL with DMEM for ScGT1cells. A 96-well, 
tissue culture-treated, clear bottom, black plate (Costar) wetted with 90 µL of DMEM, was incubated at 37°C, 
prior to use. One hundred µL of the cell suspension were added to each well and the cells were allowed to 
settle for 2 hours, prior to the addition of the test compound. Compound library stocks were prepared as 
described above and diluted 1/20 with sterile PBS prior to use at the required concentrations in 96-well plates. 
Ten µL of the compounds were added to each well, and the plates were incubated at 37°C in 5% CO2. Final 
DMSO concentration was never above 0.1% (v/v). Media were aspirated after incubation of 5 days and cells 
were washed twice with 200 µL of PBS. One hundred µL of 2.5 µM calcein-AM were added, and the plates 
were incubated at 37°C for 30 min. Fluorescence emission intensity was quantified using a SpectraMax 
Gemini EM or SpectraMax M5 fluorescence plate reader, excitation/emission ratio equal to 492/525 nm. 
PrPSc detection by western blot.  
After 5 days of drug treatment, the accumulation of PrPSc was detected by immunoblotting of lysed cells. 
One mL of lysis buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5 % nonidet P-40, 0.5 % deoxycholic acid 
sodium salt) was added to cell plates and the cell lysates were collected after centrifugation at 2,000 rpm for 5 
min in a bench microfuge (Eppendorf). The total protein amount of the samples was measured by the 
bicinchoninic acid assay (BCA) (Pierce). Five hundred µL of 1 mg/mL ScGT1 cell lysates were digested by 
20 µg/mL of PK for 1 hour at 37°C. The reaction was stopped with 2 mM phenylmethylsulphonylfluoride 
(PMSF) and the PK-digested cell lysates centrifuged at 48,000 rpm for 1 hour at 4°C in an ultracentrifuge 
(Beckman Coulter). The pellets were resuspended in 1X sample loading buffer. For the non-PK digested 
sample, 50 µg of cell lysates for ScGT1 were used and 2X loading buffer (125 mM Tris HCl, pH 6.8, 10% 2- 
mercapethanol, 4 % SDS, 0.2 % bromophenol blue, 20 % glycerol) was added in a 1:1 ratio. The samples 
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were boiled for 5 min at 100°C, loaded onto a 12% Tris-Glycine SDS- PAGE gel, and transferred overnight 
onto Immobilon P PVDF membranes (Millipore). Membranes were blocked by 5% nonfat milk, incubated 
with 1 µg/mL anti-PrP Fab D18 followed by incubation with goat anti-human IgG F(ab)2 fragment 
conjugated with horseradish peroxidase. Blots were developed with the enhanced chemiluminescent system 
(ECL, Amersham Biosciences) and visualized on Hyperfilm (Amersham Biosciences). 
PrPSc quantification by ELISA.  
PK digestion of cell lysates was as described above. PK-digested PrPSc was selectively precipitated by the 
addition of 0.5% aqueous phosphotungstic acid (PTA, Sigma-Aldrich) solution with continuous shaking at 
37°C, 350 rpm for 1 hour, and centrifuged at room temperature, 14,000 x g for 30 min. Pellets were dissolved 
and denatured in 50 µL of 8M guanidine hydrochloride (GdnHCl) in coating buffer (0.1 M sodium 
bicarbonate, pH 8.2) for 1 hour and diluted into 500 µL of coating buffer. Twenty µL of the suspension were 
transferred to 96-well MaxiSorp ELISA plates (Nunc), with each well containing 180 µL coating buffer and 
the plates were sealed and incubated overnight at 4°C. To increase the immunoreactivity of PrPSc, coated 
proteins were denatured in situ. Fifty µL of 8M GdnHCl were added to each well and incubated for 10 min at 
room temperature. The ELISA plates were washed three times with TBST (20 mM Tris-HCl, 137 mM NaCl, 
0.05% Tween-20, pH 7.5) and blocked with 200 µL of 3% BSA, made up in TBS (20 mM Tris-HCl, 137 mM 
NaCl, pH 7.5) sealed and incubated at 37°C. After 1 hour, the plates were washed three times with TBST, and 
incubated with 100 µL of anti-PrP antibody D18 (2 µg/mL) in 1% BSA/TBS, at 37°C for 2 hours. They were 
then washed seven times with TBST. One hundred µL of goat anti-human IgG Fab conjugated to HRP and 
diluted 1:1000 with 1% BSA/TBS was added to the plates and incubated at 37°C for 1 hour. Again, plates 
were washed seven times with TBST, and then developed with 100 µL of 1-step TMB (3,3’,5,5’- 
tetramethylbenzidine) Turbo ELISA HRP substrate (Pierce). The reaction was stopped by the addition of 100 
µL of 2 M sulfuric acid to the plates. Absorbance at 450 nm was measured using a microplate reader 
(VersaMax, Molecular Devices). Dose-response curves and EC50 values were computed using GraphPad 
Prism (version 4.0). 
Detection of in vitro effect of the synthesized compounds on prion fibril formation.  
Fibril formation was performed in accordance to the method previously described by Colby et al. with a 
few modifications.2 Briefly, 20 µL of the diluted compounds at indicated concentrations were added to each 
well containing 180 µL of reaction solution including 100 µg/mL MoPrP(23-230), 2 M GdnHCl and 10 µM 
ThT in 1X PBS buffer in a 96-well black plate (BD Falcon). Each sample was performed in four replicates. 
Each well contained one 3-mm glass bead (Sigma). The plate was covered with sealing tape (Fisher 
Scientific), incubated at 37°C with continuous shaking and read on SpectraMax M5 fluorescence plate reader 
(Molecular Devices) for 72 hrs by top fluorescence reading every 15 min at excitation of 444 nm and 
emission of 485 nm. 
Detection of antioxidant activity of the compounds by lipid peroxidation assay. 
Lipid peroxidation is an indicator of oxidative stress. The thiobarbituric acid reactive substances (TBARS) 
assay measures lipid hydroperoxides and aldehydes, such as malondialdehyde (MDA), in the cell media and 
lysates. The assay was performed in accordance to the method previously described Dubuisson et al..3 Briefly, 
106 ScGT1 cells were cultured in 1 mL of DMEM per each well of 6 well-plates for 24 hours. After 24 hrs, 
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the compounds with various concentrations were added to each well. After 3 hrs, the cell media were 
collected and the cells were washed twice with PBS and scraped off with 1 mL of 2.5% Trichloroacetic acid 
(TCA). After centrifugation (13,000 g, 2 min), 125 µL the supernatant was added to a mixture of 100 µL 15% 
TCA and 200 µL 0.67% (w/v) 2-thiobarbituric acid (TBA) and heated at 95oC for 20 min. After cooling, 750 
µL of 1-butanol was mixed thoroughly into the solution and centrifuged. Two hundred µL was transferred into 
96-well plates. Each sample was performed in three replicates. The fluorescence in the butanol phase was 
measured at excitation of 521 nm and emission of 552 nm by using M5 fluorescence plate reader (Molecular 
Devices). A blank was performed for each sample. Standard curves specific for the assay was created using 
MDA. 
Detection of antioxidant activity of Quinone compounds by sulforaphan (4-methylsulfinylbutyl 
isothiocyanate, SFP) assay. 
The assay was performed in accordance to the method previously described by Bolognesi et al..4 Briefly, 
ScGT1 cells were seeded in 96-well plates at 3 x 104 cells/well in DMEM. Experiments were performed after 
24 hrs of incubation at 37oC in 5% CO2 with 4-methylsulfinylbutyl isothiocyanate (2.5 µM), a potent inducer 
of cytosolic NQO1. After 24 hrs, the cells were washed and treated for 24 hrs with 1 µM of compounds. The 
antioxidant activity of compounds was evaluated after 30 minutes of incubation with 10 µM fluorescent probe 
(2’,7’-dichlorofluorescein diacetate, DCFH-DA) in PBS. After removal of DCFH-DA, the cells were 
incubated with 0.1 mM tert- butyl hydroperoxide (t-BuOOH) in PBS for 30 min. The fluorescence of the cells 
from each well was measured at excitation of 485 nm and emission of 535 nm by using M5 fluorescence plate 
reader (Molecular Devices). Each sample was performed in three replicates. 
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Appendix A 
Fragmenter is a toolkit of ChemAxon to break down molecules to smaller pieces called fragments by cleaving 
bonds. The tool is based on two sequential processes: 
First, RECAP fragments molecules based on chemical knowledge.1 The RECAP algorithm raises the 
following cleavage revision rules: 
• Never cut a hydrogen-connecting bond. 
• Never cut ring bonds.  
• Refuse a cut if the number of open bonds in any of the resulting fragments exceeds the specified 
limit. 
• Refuse a cut if the number of atoms in any of the resulting fragments is less than the predefined 
minimal atom count. 
 
Then, FragmentStatistics2 creates statistical results from the output of RECAP. Fragments are sorted by 
activity, which is calculated in form of a scoring function: 
!"  ×   !1×!1 + !2×!2 +… !"×!"  
where: 
• ac is the heavy atom count; 
• w1, w2, ..., wN are the category weights in descending order (Picomolar =1; Micromolar 
inhibitor=0.2; Less than millimolar= -0.6; Inactive = -1); 
• c1, c2, ..., cN are the fragment counts in each category, in descending activity order. 
The analysis provides a score [100 – 0] for each fragment, which gives an indication of how often a fragment 
occurs in the active and inactive structures. 
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